Tag: Model Answer

[Solved] Asssigment

✓ Verified Academic Solution Available

Executive Solution Overview

– 2 years ago **files (2)** – ## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx – ## AtrialFibrillationandPortableECGinDiagnosisandMonitoring.docx **## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx** **This is the second part and professor feedback of first part** **Feedback** Goo…

Instant Solution Download
$6.99

Immediate access to the full model answer, formatted citations, and rubric breakdown.

Need a Fresh Custom Paper?

Have this question answered from scratch according to your specific instructions and deadline.
Order on TutorsGallery →

Assignment Prompt & Instructions

– 2 years ago

**files (2)**

– ## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx

– ## AtrialFibrillationandPortableECGinDiagnosisandMonitoring.docx

**## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx**

**This is the second part and professor feedback of first part**

**Feedback** Good discussion. Please be more specific with your outcomes results when discussing hoe the tool chosen improve population outcomes."

**Chosen Evidence-Based Technology Use in Disease or Risk Factor**

-Describe and summarize the evidence-based technology identified that has been shown to improve the condition or Risk Factor for your patient population chosen.

-Compare and contrast the positives and negatives of using this technology use chosen.

**Conclusion**

-Recap points discussed in the paper

-Importance of advancements in technology

**Signature Assignment. Submit the complete paper including the conclusion**

Completion requirements

**Opened:** Monday, March 24, 2025, 11:00 AM

**Due:** Sunday, March 30, 2025, 11:00 PM

Full description of the assignment is included at the end of the syllabus.
In this section the students needs to submit a complete assignment. Which includes: Introduction, Body and Conclusion.

Introduction:

**Introduction:**

Brief overview of the health of the population chosen

-Introduce the global burden of disease OR risk factor chosen

-Importance of improving the condition and its impact on quality of life

**Body of the Paper**

**Global Burden of Disease Condition/Risk Factor**

-Describe the disease OR risk factor chosen

-What signs/symptoms are identified in the patient that can be found?

-How is it diagnosed and treated?

**Technology and Healthcare**

-Describe the paradigm shift in healthcare related to technology

-Elaborate how technology can improve health outcomes in your population

**## AtrialFibrillationandPortableECGinDiagnosisandMonitoring.docx**

5

**Atrial Fibrillation and Portable ECG in Diagnosis and Monitoring**

Name of Student

Lecturer Name

Course

Date

**Atrial Fibrillation and Portable ECG in Diagnosis and Monitoring**

**Introduction**

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affects millions of people and is an important cause of morbidity and mortality. The adult population, particularly those over 65, faces an increasing prevalence of AF due to aging, comorbidities, and lifestyle factors. AF increases the risk of stroke, heart failure and additional cardiovascular complications greatly and early detection of AF is imperative in reducing its risk. AF also carries a significant health and economic burden for other than individual health. For the sake of the improvement of patient outcomes, effective diagnosis and a continuous monitoring have to be achieved and that is achievable through the use of the technology such as the portable electrocardiogram (ECG) devices. This paper describes the global AF burden, AF clinical presentation and the paradigm shift in healthcare technology enabled by the advent of portable ECG devices assessing their impact on patient outcomes.

**Global Burden of Disease Condition**

Atrial fibrillation is a growing public health issue with increasing worldwide prevalence and incidence. AF affects over 46 million people worldwide according to the Global Burden of Disease study, and it is projected to increase with aging and prevalence of risk factors (Kornej et al., 2020). It is estimated that, in the US alone, the number of people who have AF will be 12.1 million by 2030 (CDC, 2024). AF is more likely to develop in older individuals with 6.4% prevalence at age 65–69 and 28.5% in those above 85 years (Khurshid et al., 2023). Additionally, AF is associated with increased healthcare utilization in the form of increased rates of hospitalization, emergency room visits, and an increased risk of ischemic stroke (Joglar et al., 2023).

AF has a wide range of clinical presentation from asymptomatic to severe with palpitations, dyspnea, fatigue, dizziness, chest pain (CDC, 2024). Most episodes are paroxysmal, many of which are not detected and so are missed or delayed diagnosis leading to an enhanced risk of complication thromboembolism. However, intermittent, often asymptomatic presentations often require prolonged rhythm monitoring that places it as the gold standard for diagnosis. According to current guidelines, stroke risk stratification should use the CHA2DS2-VASc score and anticoagulation therapy for high risk patients (Joglar et al., 2023). Treatment options include rate and rhythm control with medications including beta blockers, electrical cardioversion and catheter ablation, and lifestyle modifications. However, there is a lack of timely and effective monitoring; and technological innovation is needed to facilitate improved detection and management of the disease.

**Technology and Healthcare**

The introduction of digital health technologies has shaped the healthcare in a great way. Portable ECG devices are great examples of the shift toward patient centered care as they enable real time monitoring, early detection and improved disease management. Because the devices are so capable of detecting AF outside of traditional clinical settings, patients with intermittent arrhythmias who would otherwise go undiagnosed are of particular relevance (Brandes et al., 2022). This aligns with the broader movement of digital medicine through the shift towards wearable and mobile health technologies which allow for continuous monitoring for the purposes of developing personalized treatment plans and proactive interventions.

There are a number of benefits of integrating portable ECGs into clinical practice, such as increased diagnostic yield, improved patient engagement, and possible cost savings from decreased hospitalizations and emergency visits (Aljuaid et al., 2020). However, there remains doubt about the accuracy, reliability and interpretation of consumer-driven ECG readings from the public. While some AF studies have reported high sensitivity and specificity in detecting AF, challenges including false positives, the need for physician confirmation, and integration with electronic health records remain (Brandes et al., 2022). Complicating further widespread adoption are regulatory oversight, data privacy concerns, as well as disparities in access to technology. However, portable ECGs are increasingly used as an important asset of AF management, along with traditional diagnostic techniques and to improve patient outcomes.

**Chosen Evidence-Based Technology Use in Disease**

Portable ECG devices have shown a great deal of potential for improving detection and monitoring of AF. Real time rhythm assessment ECG devices incorporate single or multi lead ECG technology with incorporated smartphone apps. Research have indicated that the portable ECGs, like KardiaMobile and Apple Watch, have high sensitivity (96%) and specificity (92%) in detecting AF (Pearson 2022). The devices enable on demand ECG recording whereby patients can record arrhythmic episodes when they happen for improved diagnostic accuracy compared to regular intermittent monitoring.

Portable ECG use has been linked to better clinical outcomes including fewer emergency department visits and hospitalizations. Aljuaid et al. (2020) found that patients using smartphone based ECG monitor in comparison to the patients relying on traditional event monitor have significantly fewer clinic visits and emergency room admissions. In addition, the ability to perform continuous remote monitoring allows for timely correction of anticoagulation and antirrythmic therapy and eliminates the risk of stroke and of complications of AF (Joglar et al., 2023). Portable ECG technology is thus transformative: its ability to enable real-time data, that leads to the potential to intervene early and with personalized treatment, is a major advance in this area.

Despite these advantages, limitations exist. This could lead to unnecessary anxiety and excessive healthcare utilization through false positives. Workflow difficulties in clinical practice arise from the need for physician confirmation of automated interpretations. Further, there may be cost and accessibility issues that impact widespread adoption, especially with socioeconomically disadvantaged populations (Brandes et al., 2022). In order to address these barriers, healthcare providers, technology developers and policymakers must work together to ensure that implementation is optimized and benefits are maximized.

**Conclusion**

Atrial fibrillation is a major source of global health burden, and particularly so among the aging adult population. The ability to detect and monitor continuously is crucial for reducing complications and enhancing patient outcomes. AF diagnosis and management has been contributed by portable ECG technology, a useful tool for real-time rhythm assessment, early detection and remote monitoring. These devices provide great advantages but these devices still have to address challenges of accuracy, integration into clinical workflows and accessibility. In the coming years, the future of arrhythmia care will be shaped in large part by the continued advancement of digital health technologies and their incorporation into guideline based AF management. By combining portables ECGs with the standard monitoring approach, AF detection can be further improved, optimal treatment can be achieved, and disease burden can be reduced.

**References**

Aljuaid, M., Marashly, Q., AlDanaf, J., Tawhari, I., Barakat, M., Barakat, R., Zobell, B., Cho, W., Chelu, M. G., & Marrouche, N. F. (2020). Smartphone ECG monitoring system helps lower emergency room and clinic visits in post-atrial fibrillation ablation patients.
_Clinical Medicine Insights: Cardiology, 14_, 1-7. https://doi.org/10.1177/1179546820901508

Brandes, A., Stavrakis, S., Freedman, B., Antoniou, S., Boriani, G., Camm, A. J., Chow, C. K., Ding, E., Engdahl, J., Gibson, M. M., Golovchiner, G., Glotzer, T., Guo, Y., Healey, J. S., Hills, M. T., Johnson, L., Lip, G. Y. H., Lobban, T., Macfarlane, P. W., … Turakhia, M. P. (2022). Consumer-led screening for atrial fibrillation: Frontier review of the AF-SCREEN international collaboration.
_Circulation, 146_(1461-1474). https://doi.org/10.1161/CIRCULATIONAHA.121.058911

Centers for Disease Control and Prevention. (2024). About atrial fibrillation.
_CDC Heart Disease and Stroke Prevention._ Retrieved from
[https://www.cdc.gov/heart-disease/about/atrial-fibrillation.html](https://www.cdc.gov/heart-disease/about/atrial-fibrillation.html)

Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., … Van Wagoner, D. R. (2023). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation.
_Journal of the American College of Cardiology, 83_(1), 109-279. https://doi.org/10.1016/j.jacc.2023.08.017

Khurshid, S., Ashburner, J. M., Ellinor, P. T., McManus, D. D., Atlas, S. J., Singer, D. E., & Lubitz, S. A. (2023). Prevalence and incidence of atrial fibrillation among older primary care patients.
_JAMA Network Open, 6_(2), e2255838. https://doi.org/10.1001/jamanetworkopen.2022.55838

Kornej, J., Börschel, C. S., Benjamin, E. J., & Schnabel, R. B. (2020). Epidemiology of atrial fibrillation in the 21st century.
_Circulation Research, 127_(4), 4-20.
[https://doi.org/10.1161/CIRCRESAHA.120.316340](https://doi.org/10.1161/CIRCRESAHA.120.316340)

Pearson, V. (2022). Mobile ECG monitoring for atrial fibrillation management: A literature review.
_International Journal of Advanced Health Science and Technology, 2_(1), 19-25.
[https://doi.org/10.35882/ijahst.v2i1.4](https://doi.org/10.35882/ijahst.v2i1.4)

**## AtrialFibrillationandPortableECGinDiagnosisandMonitoring.docx**

5

**Atrial Fibrillation and Portable ECG in Diagnosis and Monitoring**

Name of Student

Lecturer Name

Course

Date

**Atrial Fibrillation and Portable ECG in Diagnosis and Monitoring**

**Introduction**

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affects millions of people and is an important cause of morbidity and mortality. The adult population, particularly those over 65, faces an increasing prevalence of AF due to aging, comorbidities, and lifestyle factors. AF increases the risk of stroke, heart failure and additional cardiovascular complications greatly and early detection of AF is imperative in reducing its risk. AF also carries a significant health and economic burden for other than individual health. For the sake of the improvement of patient outcomes, effective diagnosis and a continuous monitoring have to be achieved and that is achievable through the use of the technology such as the portable electrocardiogram (ECG) devices. This paper describes the global AF burden, AF clinical presentation and the paradigm shift in healthcare technology enabled by the advent of portable ECG devices assessing their impact on patient outcomes.

**Global Burden of Disease Condition**

Atrial fibrillation is a growing public health issue with increasing worldwide prevalence and incidence. AF affects over 46 million people worldwide according to the Global Burden of Disease study, and it is projected to increase with aging and prevalence of risk factors (Kornej et al., 2020). It is estimated that, in the US alone, the number of people who have AF will be 12.1 million by 2030 (CDC, 2024). AF is more likely to develop in older individuals with 6.4% prevalence at age 65–69 and 28.5% in those above 85 years (Khurshid et al., 2023). Additionally, AF is associated with increased healthcare utilization in the form of increased rates of hospitalization, emergency room visits, and an increased risk of ischemic stroke (Joglar et al., 2023).

AF has a wide range of clinical presentation from asymptomatic to severe with palpitations, dyspnea, fatigue, dizziness, chest pain (CDC, 2024). Most episodes are paroxysmal, many of which are not detected and so are missed or delayed diagnosis leading to an enhanced risk of complication thromboembolism. However, intermittent, often asymptomatic presentations often require prolonged rhythm monitoring that places it as the gold standard for diagnosis. According to current guidelines, stroke risk stratification should use the CHA2DS2-VASc score and anticoagulation therapy for high risk patients (Joglar et al., 2023). Treatment options include rate and rhythm control with medications including beta blockers, electrical cardioversion and catheter ablation, and lifestyle modifications. However, there is a lack of timely and effective monitoring; and technological innovation is needed to facilitate improved detection and management of the disease.

**Technology and Healthcare**

The introduction of digital health technologies has shaped the healthcare in a great way. Portable ECG devices are great examples of the shift toward patient centered care as they enable real time monitoring, early detection and improved disease management. Because the devices are so capable of detecting AF outside of traditional clinical settings, patients with intermittent arrhythmias who would otherwise go undiagnosed are of particular relevance (Brandes et al., 2022). This aligns with the broader movement of digital medicine through the shift towards wearable and mobile health technologies which allow for continuous monitoring for the purposes of developing personalized treatment plans and proactive interventions.

There are a number of benefits of integrating portable ECGs into clinical practice, such as increased diagnostic yield, improved patient engagement, and possible cost savings from decreased hospitalizations and emergency visits (Aljuaid et al., 2020). However, there remains doubt about the accuracy, reliability and interpretation of consumer-driven ECG readings from the public. While some AF studies have reported high sensitivity and specificity in detecting AF, challenges including false positives, the need for physician confirmation, and integration with electronic health records remain (Brandes et al., 2022). Complicating further widespread adoption are regulatory oversight, data privacy concerns, as well as disparities in access to technology. However, portable ECGs are increasingly used as an important asset of AF management, along with traditional diagnostic techniques and to improve patient outcomes.

**Chosen Evidence-Based Technology Use in Disease**

Portable ECG devices have shown a great deal of potential for improving detection and monitoring of AF. Real time rhythm assessment ECG devices incorporate single or multi lead ECG technology with incorporated smartphone apps. Research have indicated that the portable ECGs, like KardiaMobile and Apple Watch, have high sensitivity (96%) and specificity (92%) in detecting AF (Pearson 2022). The devices enable on demand ECG recording whereby patients can record arrhythmic episodes when they happen for improved diagnostic accuracy compared to regular intermittent monitoring.

Portable ECG use has been linked to better clinical outcomes including fewer emergency department visits and hospitalizations. Aljuaid et al. (2020) found that patients using smartphone based ECG monitor in comparison to the patients relying on traditional event monitor have significantly fewer clinic visits and emergency room admissions. In addition, the ability to perform continuous remote monitoring allows for timely correction of anticoagulation and antirrythmic therapy and eliminates the risk of stroke and of complications of AF (Joglar et al., 2023). Portable ECG technology is thus transformative: its ability to enable real-time data, that leads to the potential to intervene early and with personalized treatment, is a major advance in this area.

Despite these advantages, limitations exist. This could lead to unnecessary anxiety and excessive healthcare utilization through false positives. Workflow difficulties in clinical practice arise from the need for physician confirmation of automated interpretations. Further, there may be cost and accessibility issues that impact widespread adoption, especially with socioeconomically disadvantaged populations (Brandes et al., 2022). In order to address these barriers, healthcare providers, technology developers and policymakers must work together to ensure that implementation is optimized and benefits are maximized.

**Conclusion**

Atrial fibrillation is a major source of global health burden, and particularly so among the aging adult population. The ability to detect and monitor continuously is crucial for reducing complications and enhancing patient outcomes. AF diagnosis and management has been contributed by portable ECG technology, a useful tool for real-time rhythm assessment, early detection and remote monitoring. These devices provide great advantages but these devices still have to address challenges of accuracy, integration into clinical workflows and accessibility. In the coming years, the future of arrhythmia care will be shaped in large part by the continued advancement of digital health technologies and their incorporation into guideline based AF management. By combining portables ECGs with the standard monitoring approach, AF detection can be further improved, optimal treatment can be achieved, and disease burden can be reduced.

**References**

Aljuaid, M., Marashly, Q., AlDanaf, J., Tawhari, I., Barakat, M., Barakat, R., Zobell, B., Cho, W., Chelu, M. G., & Marrouche, N. F. (2020). Smartphone ECG monitoring system helps lower emergency room and clinic visits in post-atrial fibrillation ablation patients.
_Clinical Medicine Insights: Cardiology, 14_, 1-7. https://doi.org/10.1177/1179546820901508

Brandes, A., Stavrakis, S., Freedman, B., Antoniou, S., Boriani, G., Camm, A. J., Chow, C. K., Ding, E., Engdahl, J., Gibson, M. M., Golovchiner, G., Glotzer, T., Guo, Y., Healey, J. S., Hills, M. T., Johnson, L., Lip, G. Y. H., Lobban, T., Macfarlane, P. W., … Turakhia, M. P. (2022). Consumer-led screening for atrial fibrillation: Frontier review of the AF-SCREEN international collaboration.
_Circulation, 146_(1461-1474). https://doi.org/10.1161/CIRCULATIONAHA.121.058911

Centers for Disease Control and Prevention. (2024). About atrial fibrillation.
_CDC Heart Disease and Stroke Prevention._ Retrieved from
[https://www.cdc.gov/heart-disease/about/atrial-fibrillation.html](https://www.cdc.gov/heart-disease/about/atrial-fibrillation.html)

Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., … Van Wagoner, D. R. (2023). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation.
_Journal of the American College of Cardiology, 83_(1), 109-279. https://doi.org/10.1016/j.jacc.2023.08.017

Khurshid, S., Ashburner, J. M., Ellinor, P. T., McManus, D. D., Atlas, S. J., Singer, D. E., & Lubitz, S. A. (2023). Prevalence and incidence of atrial fibrillation among older primary care patients.
_JAMA Network Open, 6_(2), e2255838. https://doi.org/10.1001/jamanetworkopen.2022.55838

Kornej, J., Börschel, C. S., Benjamin, E. J., & Schnabel, R. B. (2020). Epidemiology of atrial fibrillation in the 21st century.
_Circulation Research, 127_(4), 4-20.
[https://doi.org/10.1161/CIRCRESAHA.120.316340](https://doi.org/10.1161/CIRCRESAHA.120.316340)

Pearson, V. (2022). Mobile ECG monitoring for atrial fibrillation management: A literature review.
_International Journal of Advanced Health Science and Technology, 2_(1), 19-25.
[https://doi.org/10.35882/ijahst.v2i1.4](https://doi.org/10.35882/ijahst.v2i1.4)

**## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx**

**This is the second part and professor feedback of first part**

**Feedback** Good discussion. Please be more specific with your outcomes results when discussing hoe the tool chosen improve population outcomes."

**Chosen Evidence-Based Technology Use in Disease or Risk Factor**

-Describe and summarize the evidence-based technology identified that has been shown to improve the condition or Risk Factor for your patient population chosen.

-Compare and contrast the positives and negatives of using this technology use chosen.

**Conclusion**

-Recap points discussed in the paper

-Importance of advancements in technology

**Signature Assignment. Submit the complete paper including the conclusion**

Completion requirements

**Opened:** Monday, March 24, 2025, 11:00 AM

**Due:** Sunday, March 30, 2025, 11:00 PM

Full description of the assignment is included at the end of the syllabus.
In this section the students needs to submit a complete assignment. Which includes: Introduction, Body and Conclusion.

Introduction:

**Introduction:**

Brief overview of the health of the population chosen

-Introduce the global burden of disease OR risk factor chosen

-Importance of improving the condition and its impact on quality of life

**Body of the Paper**

**Global Burden of Disease Condition/Risk Factor**

-Describe the disease OR risk factor chosen

-What signs/symptoms are identified in the patient that can be found?

-How is it diagnosed and treated?

**Technology and Healthcare**

-Describe the paradigm shift in healthcare related to technology

-Elaborate how technology can improve health outcomes in your population

**## AtrialFibrillationandPortableECGinDiagnosisandMonitoring.docx**

5

**Atrial Fibrillation and Portable ECG in Diagnosis and Monitoring**

Name of Student

Lecturer Name

Course

Date

**Atrial Fibrillation and Portable ECG in Diagnosis and Monitoring**

**Introduction**

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affects millions of people and is an important cause of morbidity and mortality. The adult population, particularly those over 65, faces an increasing prevalence of AF due to aging, comorbidities, and lifestyle factors. AF increases the risk of stroke, heart failure and additional cardiovascular complications greatly and early detection of AF is imperative in reducing its risk. AF also carries a significant health and economic burden for other than individual health. For the sake of the improvement of patient outcomes, effective diagnosis and a continuous monitoring have to be achieved and that is achievable through the use of the technology such as the portable electrocardiogram (ECG) devices. This paper describes the global AF burden, AF clinical presentation and the paradigm shift in healthcare technology enabled by the advent of portable ECG devices assessing their impact on patient outcomes.

**Global Burden of Disease Condition**

Atrial fibrillation is a growing public health issue with increasing worldwide prevalence and incidence. AF affects over 46 million people worldwide according to the Global Burden of Disease study, and it is projected to increase with aging and prevalence of risk factors (Kornej et al., 2020). It is estimated that, in the US alone, the number of people who have AF will be 12.1 million by 2030 (CDC, 2024). AF is more likely to develop in older individuals with 6.4% prevalence at age 65–69 and 28.5% in those above 85 years (Khurshid et al., 2023). Additionally, AF is associated with increased healthcare utilization in the form of increased rates of hospitalization, emergency room visits, and an increased risk of ischemic stroke (Joglar et al., 2023).

AF has a wide range of clinical presentation from asymptomatic to severe with palpitations, dyspnea, fatigue, dizziness, chest pain (CDC, 2024). Most episodes are paroxysmal, many of which are not detected and so are missed or delayed diagnosis leading to an enhanced risk of complication thromboembolism. However, intermittent, often asymptomatic presentations often require prolonged rhythm monitoring that places it as the gold standard for diagnosis. According to current guidelines, stroke risk stratification should use the CHA2DS2-VASc score and anticoagulation therapy for high risk patients (Joglar et al., 2023). Treatment options include rate and rhythm control with medications including beta blockers, electrical cardioversion and catheter ablation, and lifestyle modifications. However, there is a lack of timely and effective monitoring; and technological innovation is needed to facilitate improved detection and management of the disease.

**Technology and Healthcare**

The introduction of digital health technologies has shaped the healthcare in a great way. Portable ECG devices are great examples of the shift toward patient centered care as they enable real time monitoring, early detection and improved disease management. Because the devices are so capable of detecting AF outside of traditional clinical settings, patients with intermittent arrhythmias who would otherwise go undiagnosed are of particular relevance (Brandes et al., 2022). This aligns with the broader movement of digital medicine through the shift towards wearable and mobile health technologies which allow for continuous monitoring for the purposes of developing personalized treatment plans and proactive interventions.

There are a number of benefits of integrating portable ECGs into clinical practice, such as increased diagnostic yield, improved patient engagement, and possible cost savings from decreased hospitalizations and emergency visits (Aljuaid et al., 2020). However, there remains doubt about the accuracy, reliability and interpretation of consumer-driven ECG readings from the public. While some AF studies have reported high sensitivity and specificity in detecting AF, challenges including false positives, the need for physician confirmation, and integration with electronic health records remain (Brandes et al., 2022). Complicating further widespread adoption are regulatory oversight, data privacy concerns, as well as disparities in access to technology. However, portable ECGs are increasingly used as an important asset of AF management, along with traditional diagnostic techniques and to improve patient outcomes.

**Chosen Evidence-Based Technology Use in Disease**

Portable ECG devices have shown a great deal of potential for improving detection and monitoring of AF. Real time rhythm assessment ECG devices incorporate single or multi lead ECG technology with incorporated smartphone apps. Research have indicated that the portable ECGs, like KardiaMobile and Apple Watch, have high sensitivity (96%) and specificity (92%) in detecting AF (Pearson 2022). The devices enable on demand ECG recording whereby patients can record arrhythmic episodes when they happen for improved diagnostic accuracy compared to regular intermittent monitoring.

Portable ECG use has been linked to better clinical outcomes including fewer emergency department visits and hospitalizations. Aljuaid et al. (2020) found that patients using smartphone based ECG monitor in comparison to the patients relying on traditional event monitor have significantly fewer clinic visits and emergency room admissions. In addition, the ability to perform continuous remote monitoring allows for timely correction of anticoagulation and antirrythmic therapy and eliminates the risk of stroke and of complications of AF (Joglar et al., 2023). Portable ECG technology is thus transformative: its ability to enable real-time data, that leads to the potential to intervene early and with personalized treatment, is a major advance in this area.

Despite these advantages, limitations exist. This could lead to unnecessary anxiety and excessive healthcare utilization through false positives. Workflow difficulties in clinical practice arise from the need for physician confirmation of automated interpretations. Further, there may be cost and accessibility issues that impact widespread adoption, especially with socioeconomically disadvantaged populations (Brandes et al., 2022). In order to address these barriers, healthcare providers, technology developers and policymakers must work together to ensure that implementation is optimized and benefits are maximized.

**Conclusion**

Atrial fibrillation is a major source of global health burden, and particularly so among the aging adult population. The ability to detect and monitor continuously is crucial for reducing complications and enhancing patient outcomes. AF diagnosis and management has been contributed by portable ECG technology, a useful tool for real-time rhythm assessment, early detection and remote monitoring. These devices provide great advantages but these devices still have to address challenges of accuracy, integration into clinical workflows and accessibility. In the coming years, the future of arrhythmia care will be shaped in large part by the continued advancement of digital health technologies and their incorporation into guideline based AF management. By combining portables ECGs with the standard monitoring approach, AF detection can be further improved, optimal treatment can be achieved, and disease burden can be reduced.

**References**

Aljuaid, M., Marashly, Q., AlDanaf, J., Tawhari, I., Barakat, M., Barakat, R., Zobell, B., Cho, W., Chelu, M. G., & Marrouche, N. F. (2020). Smartphone ECG monitoring system helps lower emergency room and clinic visits in post-atrial fibrillation ablation patients.
_Clinical Medicine Insights: Cardiology, 14_, 1-7. https://doi.org/10.1177/1179546820901508

Brandes, A., Stavrakis, S., Freedman, B., Antoniou, S., Boriani, G., Camm, A. J., Chow, C. K., Ding, E., Engdahl, J., Gibson, M. M., Golovchiner, G., Glotzer, T., Guo, Y., Healey, J. S., Hills, M. T., Johnson, L., Lip, G. Y. H., Lobban, T., Macfarlane, P. W., … Turakhia, M. P. (2022). Consumer-led screening for atrial fibrillation: Frontier review of the AF-SCREEN international collaboration.
_Circulation, 146_(1461-1474). https://doi.org/10.1161/CIRCULATIONAHA.121.058911

Centers for Disease Control and Prevention. (2024). About atrial fibrillation.
_CDC Heart Disease and Stroke Prevention._ Retrieved from
[https://www.cdc.gov/heart-disease/about/atrial-fibrillation.html](https://www.cdc.gov/heart-disease/about/atrial-fibrillation.html)

Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., … Van Wagoner, D. R. (2023). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation.
_Journal of the American College of Cardiology, 83_(1), 109-279. https://doi.org/10.1016/j.jacc.2023.08.017

Khurshid, S., Ashburner, J. M., Ellinor, P. T., McManus, D. D., Atlas, S. J., Singer, D. E., & Lubitz, S. A. (2023). Prevalence and incidence of atrial fibrillation among older primary care patients.
_JAMA Network Open, 6_(2), e2255838. https://doi.org/10.1001/jamanetworkopen.2022.55838

Kornej, J., Börschel, C. S., Benjamin, E. J., & Schnabel, R. B. (2020). Epidemiology of atrial fibrillation in the 21st century.
_Circulation Research, 127_(4), 4-20.
[https://doi.org/10.1161/CIRCRESAHA.120.316340](https://doi.org/10.1161/CIRCRESAHA.120.316340)

Pearson, V. (2022). Mobile ECG monitoring for atrial fibrillation management: A literature review.
_International Journal of Advanced Health Science and Technology, 2_(1), 19-25.
[https://doi.org/10.35882/ijahst.v2i1.4](https://doi.org/10.35882/ijahst.v2i1.4)

**## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx**

**This is the second part and professor feedback of first part**

**Feedback** Good discussion. Please be more specific with your outcomes results when discussing hoe the tool chosen improve population outcomes."

**Chosen Evidence-Based Technology Use in Disease or Risk Factor**

-Describe and summarize the evidence-based technology identified that has been shown to improve the condition or Risk Factor for your patient population chosen.

-Compare and contrast the positives and negatives of using this technology use chosen.

**Conclusion**

-Recap points discussed in the paper

-Importance of advancements in technology

**Signature Assignment. Submit the complete paper including the conclusion**

Completion requirements

**Opened:** Monday, March 24, 2025, 11:00 AM

**Due:** Sunday, March 30, 2025, 11:00 PM

Full description of the assignment is included at the end of the syllabus.
In this section the students needs to submit a complete assignment. Which includes: Introduction, Body and Conclusion.

Introduction:

**Introduction:**

Brief overview of the health of the population chosen

-Introduce the global burden of disease OR risk factor chosen

-Importance of improving the condition and its impact on quality of life

**Body of the Paper**

**Global Burden of Disease Condition/Risk Factor**

-Describe the disease OR risk factor chosen

-What signs/symptoms are identified in the patient that can be found?

-How is it diagnosed and treated?

**Technology and Healthcare**

-Describe the paradigm shift in healthcare related to technology

-Elaborate how technology can improve health outcomes in your population

**## AtrialFibrillationandPortableECGinDiagnosisandMonitoring.docx**

5

**Atrial Fibrillation and Portable ECG in Diagnosis and Monitoring**

Name of Student

Lecturer Name

Course

Date

**Atrial Fibrillation and Portable ECG in Diagnosis and Monitoring**

**Introduction**

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affects millions of people and is an important cause of morbidity and mortality. The adult population, particularly those over 65, faces an increasing prevalence of AF due to aging, comorbidities, and lifestyle factors. AF increases the risk of stroke, heart failure and additional cardiovascular complications greatly and early detection of AF is imperative in reducing its risk. AF also carries a significant health and economic burden for other than individual health. For the sake of the improvement of patient outcomes, effective diagnosis and a continuous monitoring have to be achieved and that is achievable through the use of the technology such as the portable electrocardiogram (ECG) devices. This paper describes the global AF burden, AF clinical presentation and the paradigm shift in healthcare technology enabled by the advent of portable ECG devices assessing their impact on patient outcomes.

**Global Burden of Disease Condition**

Atrial fibrillation is a growing public health issue with increasing worldwide prevalence and incidence. AF affects over 46 million people worldwide according to the Global Burden of Disease study, and it is projected to increase with aging and prevalence of risk factors (Kornej et al., 2020). It is estimated that, in the US alone, the number of people who have AF will be 12.1 million by 2030 (CDC, 2024). AF is more likely to develop in older individuals with 6.4% prevalence at age 65–69 and 28.5% in those above 85 years (Khurshid et al., 2023). Additionally, AF is associated with increased healthcare utilization in the form of increased rates of hospitalization, emergency room visits, and an increased risk of ischemic stroke (Joglar et al., 2023).

AF has a wide range of clinical presentation from asymptomatic to severe with palpitations, dyspnea, fatigue, dizziness, chest pain (CDC, 2024). Most episodes are paroxysmal, many of which are not detected and so are missed or delayed diagnosis leading to an enhanced risk of complication thromboembolism. However, intermittent, often asymptomatic presentations often require prolonged rhythm monitoring that places it as the gold standard for diagnosis. According to current guidelines, stroke risk stratification should use the CHA2DS2-VASc score and anticoagulation therapy for high risk patients (Joglar et al., 2023). Treatment options include rate and rhythm control with medications including beta blockers, electrical cardioversion and catheter ablation, and lifestyle modifications. However, there is a lack of timely and effective monitoring; and technological innovation is needed to facilitate improved detection and management of the disease.

**Technology and Healthcare**

The introduction of digital health technologies has shaped the healthcare in a great way. Portable ECG devices are great examples of the shift toward patient centered care as they enable real time monitoring, early detection and improved disease management. Because the devices are so capable of detecting AF outside of traditional clinical settings, patients with intermittent arrhythmias who would otherwise go undiagnosed are of particular relevance (Brandes et al., 2022). This aligns with the broader movement of digital medicine through the shift towards wearable and mobile health technologies which allow for continuous monitoring for the purposes of developing personalized treatment plans and proactive interventions.

There are a number of benefits of integrating portable ECGs into clinical practice, such as increased diagnostic yield, improved patient engagement, and possible cost savings from decreased hospitalizations and emergency visits (Aljuaid et al., 2020). However, there remains doubt about the accuracy, reliability and interpretation of consumer-driven ECG readings from the public. While some AF studies have reported high sensitivity and specificity in detecting AF, challenges including false positives, the need for physician confirmation, and integration with electronic health records remain (Brandes et al., 2022). Complicating further widespread adoption are regulatory oversight, data privacy concerns, as well as disparities in access to technology. However, portable ECGs are increasingly used as an important asset of AF management, along with traditional diagnostic techniques and to improve patient outcomes.

**Chosen Evidence-Based Technology Use in Disease**

Portable ECG devices have shown a great deal of potential for improving detection and monitoring of AF. Real time rhythm assessment ECG devices incorporate single or multi lead ECG technology with incorporated smartphone apps. Research have indicated that the portable ECGs, like KardiaMobile and Apple Watch, have high sensitivity (96%) and specificity (92%) in detecting AF (Pearson 2022). The devices enable on demand ECG recording whereby patients can record arrhythmic episodes when they happen for improved diagnostic accuracy compared to regular intermittent monitoring.

Portable ECG use has been linked to better clinical outcomes including fewer emergency department visits and hospitalizations. Aljuaid et al. (2020) found that patients using smartphone based ECG monitor in comparison to the patients relying on traditional event monitor have significantly fewer clinic visits and emergency room admissions. In addition, the ability to perform continuous remote monitoring allows for timely correction of anticoagulation and antirrythmic therapy and eliminates the risk of stroke and of complications of AF (Joglar et al., 2023). Portable ECG technology is thus transformative: its ability to enable real-time data, that leads to the potential to intervene early and with personalized treatment, is a major advance in this area.

Despite these advantages, limitations exist. This could lead to unnecessary anxiety and excessive healthcare utilization through false positives. Workflow difficulties in clinical practice arise from the need for physician confirmation of automated interpretations. Further, there may be cost and accessibility issues that impact widespread adoption, especially with socioeconomically disadvantaged populations (Brandes et al., 2022). In order to address these barriers, healthcare providers, technology developers and policymakers must work together to ensure that implementation is optimized and benefits are maximized.

**Conclusion**

Atrial fibrillation is a major source of global health burden, and particularly so among the aging adult population. The ability to detect and monitor continuously is crucial for reducing complications and enhancing patient outcomes. AF diagnosis and management has been contributed by portable ECG technology, a useful tool for real-time rhythm assessment, early detection and remote monitoring. These devices provide great advantages but these devices still have to address challenges of accuracy, integration into clinical workflows and accessibility. In the coming years, the future of arrhythmia care will be shaped in large part by the continued advancement of digital health technologies and their incorporation into guideline based AF management. By combining portables ECGs with the standard monitoring approach, AF detection can be further improved, optimal treatment can be achieved, and disease burden can be reduced.

**References**

Aljuaid, M., Marashly, Q., AlDanaf, J., Tawhari, I., Barakat, M., Barakat, R., Zobell, B., Cho, W., Chelu, M. G., & Marrouche, N. F. (2020). Smartphone ECG monitoring system helps lower emergency room and clinic visits in post-atrial fibrillation ablation patients.
_Clinical Medicine Insights: Cardiology, 14_, 1-7. https://doi.org/10.1177/1179546820901508

Brandes, A., Stavrakis, S., Freedman, B., Antoniou, S., Boriani, G., Camm, A. J., Chow, C. K., Ding, E., Engdahl, J., Gibson, M. M., Golovchiner, G., Glotzer, T., Guo, Y., Healey, J. S., Hills, M. T., Johnson, L., Lip, G. Y. H., Lobban, T., Macfarlane, P. W., … Turakhia, M. P. (2022). Consumer-led screening for atrial fibrillation: Frontier review of the AF-SCREEN international collaboration.
_Circulation, 146_(1461-1474). https://doi.org/10.1161/CIRCULATIONAHA.121.058911

Centers for Disease Control and Prevention. (2024). About atrial fibrillation.
_CDC Heart Disease and Stroke Prevention._ Retrieved from
[https://www.cdc.gov/heart-disease/about/atrial-fibrillation.html](https://www.cdc.gov/heart-disease/about/atrial-fibrillation.html)

Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., … Van Wagoner, D. R. (2023). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation.
_Journal of the American College of Cardiology, 83_(1), 109-279. https://doi.org/10.1016/j.jacc.2023.08.017

Khurshid, S., Ashburner, J. M., Ellinor, P. T., McManus, D. D., Atlas, S. J., Singer, D. E., & Lubitz, S. A. (2023). Prevalence and incidence of atrial fibrillation among older primary care patients.
_JAMA Network Open, 6_(2), e2255838. https://doi.org/10.1001/jamanetworkopen.2022.55838

Kornej, J., Börschel, C. S., Benjamin, E. J., & Schnabel, R. B. (2020). Epidemiology of atrial fibrillation in the 21st century.
_Circulation Research, 127_(4), 4-20.
[https://doi.org/10.1161/CIRCRESAHA.120.316340](https://doi.org/10.1161/CIRCRESAHA.120.316340)

Pearson, V. (2022). Mobile ECG monitoring for atrial fibrillation management: A literature review.
_International Journal of Advanced Health Science and Technology, 2_(1), 19-25.
[https://doi.org/10.35882/ijahst.v2i1.4](https://doi.org/10.35882/ijahst.v2i1.4)

November 5, 2026
[Solved] Responses

✓ Verified Academic Solution Available

Executive Solution Overview

In response to your peers, share your experience with a similar problem and share any insights that you have gained from that experience. – [\ \ Responses.docx](https://www.sweetstudy.com/files/responses-docx-10239573 "Responses.docx") – 2 years ago

Instant Solution Download
$6.99

Immediate access to the full model answer, formatted citations, and rubric breakdown.

Need a Fresh Custom Paper?

Have this question answered from scratch according to your specific instructions and deadline.
Order on TutorsGallery →

Assignment Prompt & Instructions

In response to your peers, share your experience with a similar problem and share any insights that you have gained from that experience.

– [\
\
Responses.docx](https://www.sweetstudy.com/files/responses-docx-10239573 "Responses.docx")

– 2 years ago

November 5, 2026
[Solved] Nursing homework

✓ Verified Academic Solution Available

Executive Solution Overview

– 2 years ago **files (1)** – ## NUR6400SignatureAssignment21.docx **## NUR6400SignatureAssignment21.docx** ![A blue and white logo Description automatically generated](https://www.sweetstudy.com/questions/nursing-homework-20894553) **SCHOOL OF NURSING GRADUATE STUDIES** **MASTER OF SCIENCE IN NURSI…

Instant Solution Download
$6.99

Immediate access to the full model answer, formatted citations, and rubric breakdown.

Need a Fresh Custom Paper?

Have this question answered from scratch according to your specific instructions and deadline.
Order on TutorsGallery →

Assignment Prompt & Instructions

– 2 years ago

**files (1)**

– ## NUR6400SignatureAssignment21.docx

**## NUR6400SignatureAssignment21.docx**

![A blue and white logo Description automatically generated](https://www.sweetstudy.com/questions/nursing-homework-20894553)

**SCHOOL OF NURSING GRADUATE STUDIES**

**MASTER OF SCIENCE IN NURSING – FNP**

**NUR6400 Role Development in Family Practice: Clinical Integration**

**Signature Assignment**

Understanding the role technology plays in advanced primary care to vulnerable populations is vital to ensure proper and timely diagnosis and treatment to improve healthcare outcomes for the patient. The purpose of this assignment is to evaluate one global burden of disease OR risk factor in the family population (pediatric, adult, or geriatric) and explore one current evidence-based technology use that can offer improvement of outcomes and access to the population chosen.

This assignment will focus on the following course student learning outcomes (CSLO):

1. Generate knowledge from clinical practice to improve practice and patient outcomes (EOPSLO# 4, 9).

2. Leads practice inquiry, individually or in partnership with others (EOPSLO# 2, 3, 4, 7).

3. Translates research and other forms of knowledge to improve practice processes and outcomes (EOPSLO# 9).

4. Evaluate the relationships among access, cost, quality, and safety and their influence on healthcare (EOPSLO# 3, 6, 9).

5. Collaborates in planning for transitions across the continuum of care (EOPSLO# 2, 7).

6. Integrates ethical principles in decision-making (EOPSLO# 6, 9).

7. Integrates appropriate technologies for knowledge management to improve healthcare (EOPSLO# 5).

8. Evaluate the effectiveness of the plan of care for the family, as well as the individual, and implement changes (EOPSLO# 8).

Instructions: Please choose one global burden of disease and one population (adult, pediatric, or geriatric). Once the population is chosen, find one evidence-based technology to help support the improvement of outcomes in the global burden of disease chosen.

**You are to write a three-to-five-page paper in APA format 7th edition with the following sections and level 2 headings:**

**Introduction:**

Brief overview of the health of the population chosen

-Introduce the global burden of disease OR risk factor chosen

-Importance of improving the condition and its impact on quality of life

**Body of the Paper**

**Global Burden of Disease Condition/Risk Factor**

-Describe the disease OR risk factor chosen

-What signs/symptoms are identified in the patient that can be found?

-How is it diagnosed and treated?

**Technology and Healthcare**

-Describe the paradigm shift in healthcare related to technology

-Elaborate how technology can improve health outcomes in your population

**Chosen Evidence-Based Technology Use in Disease or Risk Factor**

-Describe and summarize the evidence-based technology identified that has been shown to improve the condition or Risk Factor for your patient population chosen.

-Compare and contrast the positives and negatives of using this technology use chosen.

**Conclusion**

-Recap points discussed in the paper

-Importance of advancements in technology

Optional Resources:

https://www.thelancet.com/gbd/summaries

https://www.healthdata.org/research-analysis/library/what-global-burden-disease-gbd

## image1.jpeg

**## NUR6400SignatureAssignment21.docx**

![A blue and white logo Description automatically generated](https://www.sweetstudy.com/questions/nursing-homework-20894553)

**SCHOOL OF NURSING GRADUATE STUDIES**

**MASTER OF SCIENCE IN NURSING – FNP**

**NUR6400 Role Development in Family Practice: Clinical Integration**

**Signature Assignment**

Understanding the role technology plays in advanced primary care to vulnerable populations is vital to ensure proper and timely diagnosis and treatment to improve healthcare outcomes for the patient. The purpose of this assignment is to evaluate one global burden of disease OR risk factor in the family population (pediatric, adult, or geriatric) and explore one current evidence-based technology use that can offer improvement of outcomes and access to the population chosen.

This assignment will focus on the following course student learning outcomes (CSLO):

1. Generate knowledge from clinical practice to improve practice and patient outcomes (EOPSLO# 4, 9).

2. Leads practice inquiry, individually or in partnership with others (EOPSLO# 2, 3, 4, 7).

3. Translates research and other forms of knowledge to improve practice processes and outcomes (EOPSLO# 9).

4. Evaluate the relationships among access, cost, quality, and safety and their influence on healthcare (EOPSLO# 3, 6, 9).

5. Collaborates in planning for transitions across the continuum of care (EOPSLO# 2, 7).

6. Integrates ethical principles in decision-making (EOPSLO# 6, 9).

7. Integrates appropriate technologies for knowledge management to improve healthcare (EOPSLO# 5).

8. Evaluate the effectiveness of the plan of care for the family, as well as the individual, and implement changes (EOPSLO# 8).

Instructions: Please choose one global burden of disease and one population (adult, pediatric, or geriatric). Once the population is chosen, find one evidence-based technology to help support the improvement of outcomes in the global burden of disease chosen.

**You are to write a three-to-five-page paper in APA format 7th edition with the following sections and level 2 headings:**

**Introduction:**

Brief overview of the health of the population chosen

-Introduce the global burden of disease OR risk factor chosen

-Importance of improving the condition and its impact on quality of life

**Body of the Paper**

**Global Burden of Disease Condition/Risk Factor**

-Describe the disease OR risk factor chosen

-What signs/symptoms are identified in the patient that can be found?

-How is it diagnosed and treated?

**Technology and Healthcare**

-Describe the paradigm shift in healthcare related to technology

-Elaborate how technology can improve health outcomes in your population

**Chosen Evidence-Based Technology Use in Disease or Risk Factor**

-Describe and summarize the evidence-based technology identified that has been shown to improve the condition or Risk Factor for your patient population chosen.

-Compare and contrast the positives and negatives of using this technology use chosen.

**Conclusion**

-Recap points discussed in the paper

-Importance of advancements in technology

Optional Resources:

https://www.thelancet.com/gbd/summaries

https://www.healthdata.org/research-analysis/library/what-global-burden-disease-gbd

## image1.jpeg

November 5, 2026
[Solved] Judaism Discussion

✓ Verified Academic Solution Available

Executive Solution Overview

After studying [Module 3: Lecture Materials & Resources](https://stu.instructure.com/courses/44039/pages/g338817425654d542c3b45c5059ce7bba "Module 3: Lecture Materials & Resources"), as well as reviewing the [Judaism Resources](https://stu.instructure.com/courses/44039/pages/gc673605ed521e9809811a6f…

Instant Solution Download
$6.99

Immediate access to the full model answer, formatted citations, and rubric breakdown.

Need a Fresh Custom Paper?

Have this question answered from scratch according to your specific instructions and deadline.
Order on TutorsGallery →

Assignment Prompt & Instructions

After studying [Module 3: Lecture Materials & Resources](https://stu.instructure.com/courses/44039/pages/g338817425654d542c3b45c5059ce7bba "Module 3: Lecture Materials & Resources"), as well as reviewing the [Judaism Resources](https://stu.instructure.com/courses/44039/pages/gc673605ed521e9809811a6f01cda26d2 "Judaism Resources") page, discuss the following:

In your reading of _Chapter 10 – Encountering Judaism: The Way of God’s People_ as well as the other readings for the week, you have gained a better understanding of central themes of Judaism. As you learned more about the religion, you may have noticed the many similarities that Judaism shares with Christianity as the relationship between the two religions rather unique. Christianity is rooted in Judaism historically, scripturally, liturgically, and even theologically. No two major world religions have so much in common. Below are a handful of the common elements shared by these two religions, however it is important to note that even though these religions share several common elements, they articulate them differently. Last week, we expounded upon how some of these themes are understood in the context of Catholicism and now you will describe how they are understood in Judaism.

**Select two themes** from the list below and present the Jewish teaching on the chosen theme.

– Jewish Understanding of God
– Salvation
– Creation
– Eschatology
– Pain and Suffering
– Freedom and Free Will
– Virtues
– Sin

_**Each selected theme**_ **must:**

– Be explained in at least one paragraph
– Incorporate at least 2 direct quotations with accompanying in-text citations from either the required weekly readings or a resource found on the “Judaism Resources” page linked below.
– Your initial post should incorporate 2 different sources, formatted and cited as the instructor indicated in the announcements.

– 2 years ago

November 5, 2026
[Solved] Asssigment

✓ Verified Academic Solution Available

Executive Solution Overview

– 2 years ago **files (2)** – ## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx – ## DiabetesType11.docx **## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx** **This is the second part and professor feedback of first part** **Feedback** make sure to use an appropriate tool on week …

Instant Solution Download
$6.99

Immediate access to the full model answer, formatted citations, and rubric breakdown.

Need a Fresh Custom Paper?

Have this question answered from scratch according to your specific instructions and deadline.
Order on TutorsGallery →

Assignment Prompt & Instructions

– 2 years ago

**files (2)**

– ## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx

– ## DiabetesType11.docx

**## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx**

**This is the second part and professor feedback of first part**

**Feedback** make sure to use an appropriate tool on week 12 when evaluating the outcomes,

**Chosen Evidence-Based Technology Use in Disease or Risk Factor**

-Describe and summarize the evidence-based technology identified that has been shown to improve the condition or Risk Factor for your patient population chosen.

-Compare and contrast the positives and negatives of using this technology use chosen.

**Conclusion**

-Recap points discussed in the paper

-Importance of advancements in technology

**Signature Assignment. Submit the complete paper including the conclusion**

Completion requirements

**Opened:** Monday, March 24, 2025, 11:00 AM

**Due:** Sunday, March 30, 2025, 11:00 PM

Full description of the assignment is included at the end of the syllabus.
In this section the students needs to submit a complete assignment. Which includes: Introduction, Body and Conclusion.

Introduction:

**Introduction:**

Brief overview of the health of the population chosen

-Introduce the global burden of disease OR risk factor chosen

-Importance of improving the condition and its impact on quality of life

**Body of the Paper**

**Global Burden of Disease Condition/Risk Factor**

-Describe the disease OR risk factor chosen

-What signs/symptoms are identified in the patient that can be found?

-How is it diagnosed and treated?

**Technology and Healthcare**

-Describe the paradigm shift in healthcare related to technology

-Elaborate how technology can improve health outcomes in your population

**## DiabetesType11.docx**

Diabetes Type 1: Improving Outcomes through Technology

Student

Instructor

University affiliation

Class Name

Date

**Diabetes Type 1: Improving Outcomes through Technology**

**Introduction**

Children and young adults develop Type 1 diabetes which needs continuous life-long healthcare. The immune system accidentally damages pancreatic beta cells that make insulin which causes insulin to drop below normal levels. Type 2 diabetes normally develops because of unhealthy behaviors yet Type 1 diabetes depends mainly on genetics and surrounding conditions. The world experiences rising numbers of people affected by T1D which now totals 9 million cases. People with T1D need to control their blood sugar levels to avoid developing life-threatening DKA and avoid nerve and heart diseases plus eye problems (Addala et al., 2021). Uncontrolled diabetes causes patients to need frequent hospital visits and eventually becomes disabling. As technology keeps advancing people with diabetes can now receive better treatment options to improve their health and daily life. Advanced digital health solutions such as CGM and insulin pumps alongside digital health technology now help patients manage their diabetes care better.

**Global Burden of Disease Condition**

The global health problem of T1D mainly affects children and teenagers with no age or geographic boundaries. More T1D cases require us to find better ways to provide healthcare services to patients. People with Type 1 Diabetes need insulin treatment to survive since their condition differs from Type 2 which responds to lifestyle changes. The body's immune system starts hurting the pancreas for no clear reasons with T1D and this disease develops unpredictably (Agarwal et al., 2021).

**Signs and Symptoms**

T1D develops when patients show hyperglycemic effects such as intense thirst (polydipsia), heavy urination (polyuria), unexpected weight loss, persistent tiredness, and vision problems. Young people typically display changes in their moods and do not pay attention well during class time. When T1D remains untreated it turns into DKA which becomes an emergency condition that causes strong nausea and vomiting plus stomach pain alongside sweet breath smells and confusion before putting a patient into a coma. Patients need urgent medical care at the hospital to treat DKA.

**Diagnosis and Treatment**

Doctors identify Type 1 diabetes using multiple blood measurements including how patients handle fasting glucose levels and HbA1c alongside tests for autoantibodies linked to diabetes. When people with diabetes experience symptoms and their blood sugar levels exceed 200 mg/dL on a random test it signifies they have the condition. Patients who receive their T1D diagnosis need permanent insulin treatment either through multiple daily injections or continuous subcutaneous insulin infusions pumping (CGMS) systems. Beside insulin treatment T1D management needs patients to track their diet habits and activities plus perform regular glucose tests to prevent dangerous blood sugar levels. Our aim is to manage blood glucose values at certain levels to decrease the chances of developing diabetes complications.

**Technology and Healthcare**

Technology has transformed how healthcare manages chronic diseases across all settings of care. Modern medical devices such as CGM systems insulin pumps and artificial pancreas systems revolutionize how healthcare professionals handle diabetes. Our new technologies show blood sugar levels in real time while controlling insulin actions and sharing performance results. New digital healthcare tools help patients talk to doctors online in real time which makes them visit hospitals less often.

**Improving Health Outcomes through Technology**

New technology enhances T1D management by showing blood sugar data in real time plus alerts patients before extreme glucose changes and decreases their risk of severe hypoglycemia and hyperglycemia. The healthcare provider monitors patient glucose data from a distance and customizes health care approach based on results. The diabetes management mobile apps allow patients to measure their food carbs while recording their insulin and exercise habits. Researchers test how machine learning and artificial intelligence technologies can identify future blood sugar patterns and suggest custom insulin changes.

**Chosen Evidence-Based Technology Use in Disease Management**

Continuous Glucose Monitoring (CGM) technology has emerged as an important tool to manage Type 1 diabetes better. CGMs show blood sugar numbers right now and help detect dangerous blood sugar drops and rises which enable better T1D handling. With CGMs patients avoid frequent fingerprick blood tests because these devices directly monitor glucose levels from beneath the skin.

**Benefits of CGM Use**

Research proves that continuous glucose monitoring (CGM) systems lower HbA1c readings while making glucose levels more steady and lowering how often severe hypoglycemia happens (Majidi et al., 2021). CGMs help patients better control their condition while lowering diabetes stress and enhancing their lifestyle. CGM systems help patients spot dangerous blood sugar levels so they can start treatment at once to avoid health problems. Shoppers today can connect their CGMs to smartphone applications which show their blood sugar levels in real time and let them pass results to doctors for better care. CGMs help parents monitor their children's blood sugar levels from any location which brings peace to both parties.

**Challenges of CGM Use**

While CGM offers many benefits new users encounter substantial issues including high expense and limited availability plus short sensor life. Insurance companies do not support CGM payment which becomes expensive for many patients to afford. Some patients find sensor placement uncomfortable and deal with too many data points that cause them to get tired of using the system. The device shows imprecise measurements when the user has incorrect hydration levels or improper device setup steps. Technology enhancements create better CGMs that are easier to use and less expensive (Eberle & Stichling, 2021). Modern CGM systems let users wear sensors for longer periods because both sensor and pump connect automatically during factory calibration.

**Conclusion**

Technology integration in diabetes care brings better healthcare results especially to Type 1 Diabetes patients. Continuous Glucose Monitoring technology leads to improved blood sugar control and reduced health problems while making life for patients much better. The future of diabetes treatment depends on new developments in digital health through artificial pancreas technology which regulates insulin delivery based on live glucose measurements. Healthcare technology advances require us to make patient resources available at reasonable costs while teaching people how to use these tools effectively. Medical groups and government agencies must work together with research experts to provide people with new diabetes control methods. Using technology systems can help healthcare teams deliver better care to people with T1D which leads to better health results and enhances their daily life.

References

Addala, A., Auzanneau, M., Miller, K., Maier, W., Foster, N., Kapellen, T., … & Holl, R. W. (2021). A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: a transatlantic comparison.
_Diabetes Care_,
_44_(1), 133-140.
[https://doi.org/10.2337/dc20-0257](https://doi.org/10.2337/dc20-0257)

Agarwal, S., Schechter, C., Gonzalez, J., & Long, J. A. (2021). Racial–ethnic disparities in diabetes technology use among young adults with type 1 diabetes.
_Diabetes Technology & Therapeutics_,
_23_(4), 306-313.
[https://doi.org/10.1089/dia.2020.0338](https://doi.org/10.1089/dia.2020.0338)

Eberle, C., & Stichling, S. (2021). Clinical improvements by telemedicine interventions managing type 1 and type 2 diabetes: systematic meta-review.
_Journal of medical Internet research_,
_23_(2), e23244.
[https://doi.org/10.2196/23244](https://doi.org/10.2196/23244)

Majidi, S., Ebekozien, O., Noor, N., Lyons, S. K., McDonough, R., Gandhi, K., … & T1D Exchange Quality Improvement Collaborative Study Group. (2021). Inequities in health outcomes in children and adults with type 1 diabetes: data from the T1D Exchange Quality Improvement Collaborative.
_Clinical Diabetes_,
_39_(3), 278-283.
[https://doi.org/10.2337/cd21-0028](https://doi.org/10.2337/cd21-0028)

**## DiabetesType11.docx**

Diabetes Type 1: Improving Outcomes through Technology

Student

Instructor

University affiliation

Class Name

Date

**Diabetes Type 1: Improving Outcomes through Technology**

**Introduction**

Children and young adults develop Type 1 diabetes which needs continuous life-long healthcare. The immune system accidentally damages pancreatic beta cells that make insulin which causes insulin to drop below normal levels. Type 2 diabetes normally develops because of unhealthy behaviors yet Type 1 diabetes depends mainly on genetics and surrounding conditions. The world experiences rising numbers of people affected by T1D which now totals 9 million cases. People with T1D need to control their blood sugar levels to avoid developing life-threatening DKA and avoid nerve and heart diseases plus eye problems (Addala et al., 2021). Uncontrolled diabetes causes patients to need frequent hospital visits and eventually becomes disabling. As technology keeps advancing people with diabetes can now receive better treatment options to improve their health and daily life. Advanced digital health solutions such as CGM and insulin pumps alongside digital health technology now help patients manage their diabetes care better.

**Global Burden of Disease Condition**

The global health problem of T1D mainly affects children and teenagers with no age or geographic boundaries. More T1D cases require us to find better ways to provide healthcare services to patients. People with Type 1 Diabetes need insulin treatment to survive since their condition differs from Type 2 which responds to lifestyle changes. The body's immune system starts hurting the pancreas for no clear reasons with T1D and this disease develops unpredictably (Agarwal et al., 2021).

**Signs and Symptoms**

T1D develops when patients show hyperglycemic effects such as intense thirst (polydipsia), heavy urination (polyuria), unexpected weight loss, persistent tiredness, and vision problems. Young people typically display changes in their moods and do not pay attention well during class time. When T1D remains untreated it turns into DKA which becomes an emergency condition that causes strong nausea and vomiting plus stomach pain alongside sweet breath smells and confusion before putting a patient into a coma. Patients need urgent medical care at the hospital to treat DKA.

**Diagnosis and Treatment**

Doctors identify Type 1 diabetes using multiple blood measurements including how patients handle fasting glucose levels and HbA1c alongside tests for autoantibodies linked to diabetes. When people with diabetes experience symptoms and their blood sugar levels exceed 200 mg/dL on a random test it signifies they have the condition. Patients who receive their T1D diagnosis need permanent insulin treatment either through multiple daily injections or continuous subcutaneous insulin infusions pumping (CGMS) systems. Beside insulin treatment T1D management needs patients to track their diet habits and activities plus perform regular glucose tests to prevent dangerous blood sugar levels. Our aim is to manage blood glucose values at certain levels to decrease the chances of developing diabetes complications.

**Technology and Healthcare**

Technology has transformed how healthcare manages chronic diseases across all settings of care. Modern medical devices such as CGM systems insulin pumps and artificial pancreas systems revolutionize how healthcare professionals handle diabetes. Our new technologies show blood sugar levels in real time while controlling insulin actions and sharing performance results. New digital healthcare tools help patients talk to doctors online in real time which makes them visit hospitals less often.

**Improving Health Outcomes through Technology**

New technology enhances T1D management by showing blood sugar data in real time plus alerts patients before extreme glucose changes and decreases their risk of severe hypoglycemia and hyperglycemia. The healthcare provider monitors patient glucose data from a distance and customizes health care approach based on results. The diabetes management mobile apps allow patients to measure their food carbs while recording their insulin and exercise habits. Researchers test how machine learning and artificial intelligence technologies can identify future blood sugar patterns and suggest custom insulin changes.

**Chosen Evidence-Based Technology Use in Disease Management**

Continuous Glucose Monitoring (CGM) technology has emerged as an important tool to manage Type 1 diabetes better. CGMs show blood sugar numbers right now and help detect dangerous blood sugar drops and rises which enable better T1D handling. With CGMs patients avoid frequent fingerprick blood tests because these devices directly monitor glucose levels from beneath the skin.

**Benefits of CGM Use**

Research proves that continuous glucose monitoring (CGM) systems lower HbA1c readings while making glucose levels more steady and lowering how often severe hypoglycemia happens (Majidi et al., 2021). CGMs help patients better control their condition while lowering diabetes stress and enhancing their lifestyle. CGM systems help patients spot dangerous blood sugar levels so they can start treatment at once to avoid health problems. Shoppers today can connect their CGMs to smartphone applications which show their blood sugar levels in real time and let them pass results to doctors for better care. CGMs help parents monitor their children's blood sugar levels from any location which brings peace to both parties.

**Challenges of CGM Use**

While CGM offers many benefits new users encounter substantial issues including high expense and limited availability plus short sensor life. Insurance companies do not support CGM payment which becomes expensive for many patients to afford. Some patients find sensor placement uncomfortable and deal with too many data points that cause them to get tired of using the system. The device shows imprecise measurements when the user has incorrect hydration levels or improper device setup steps. Technology enhancements create better CGMs that are easier to use and less expensive (Eberle & Stichling, 2021). Modern CGM systems let users wear sensors for longer periods because both sensor and pump connect automatically during factory calibration.

**Conclusion**

Technology integration in diabetes care brings better healthcare results especially to Type 1 Diabetes patients. Continuous Glucose Monitoring technology leads to improved blood sugar control and reduced health problems while making life for patients much better. The future of diabetes treatment depends on new developments in digital health through artificial pancreas technology which regulates insulin delivery based on live glucose measurements. Healthcare technology advances require us to make patient resources available at reasonable costs while teaching people how to use these tools effectively. Medical groups and government agencies must work together with research experts to provide people with new diabetes control methods. Using technology systems can help healthcare teams deliver better care to people with T1D which leads to better health results and enhances their daily life.

References

Addala, A., Auzanneau, M., Miller, K., Maier, W., Foster, N., Kapellen, T., … & Holl, R. W. (2021). A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: a transatlantic comparison.
_Diabetes Care_,
_44_(1), 133-140.
[https://doi.org/10.2337/dc20-0257](https://doi.org/10.2337/dc20-0257)

Agarwal, S., Schechter, C., Gonzalez, J., & Long, J. A. (2021). Racial–ethnic disparities in diabetes technology use among young adults with type 1 diabetes.
_Diabetes Technology & Therapeutics_,
_23_(4), 306-313.
[https://doi.org/10.1089/dia.2020.0338](https://doi.org/10.1089/dia.2020.0338)

Eberle, C., & Stichling, S. (2021). Clinical improvements by telemedicine interventions managing type 1 and type 2 diabetes: systematic meta-review.
_Journal of medical Internet research_,
_23_(2), e23244.
[https://doi.org/10.2196/23244](https://doi.org/10.2196/23244)

Majidi, S., Ebekozien, O., Noor, N., Lyons, S. K., McDonough, R., Gandhi, K., … & T1D Exchange Quality Improvement Collaborative Study Group. (2021). Inequities in health outcomes in children and adults with type 1 diabetes: data from the T1D Exchange Quality Improvement Collaborative.
_Clinical Diabetes_,
_39_(3), 278-283.
[https://doi.org/10.2337/cd21-0028](https://doi.org/10.2337/cd21-0028)

**## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx**

**This is the second part and professor feedback of first part**

**Feedback** make sure to use an appropriate tool on week 12 when evaluating the outcomes,

**Chosen Evidence-Based Technology Use in Disease or Risk Factor**

-Describe and summarize the evidence-based technology identified that has been shown to improve the condition or Risk Factor for your patient population chosen.

-Compare and contrast the positives and negatives of using this technology use chosen.

**Conclusion**

-Recap points discussed in the paper

-Importance of advancements in technology

**Signature Assignment. Submit the complete paper including the conclusion**

Completion requirements

**Opened:** Monday, March 24, 2025, 11:00 AM

**Due:** Sunday, March 30, 2025, 11:00 PM

Full description of the assignment is included at the end of the syllabus.
In this section the students needs to submit a complete assignment. Which includes: Introduction, Body and Conclusion.

Introduction:

**Introduction:**

Brief overview of the health of the population chosen

-Introduce the global burden of disease OR risk factor chosen

-Importance of improving the condition and its impact on quality of life

**Body of the Paper**

**Global Burden of Disease Condition/Risk Factor**

-Describe the disease OR risk factor chosen

-What signs/symptoms are identified in the patient that can be found?

-How is it diagnosed and treated?

**Technology and Healthcare**

-Describe the paradigm shift in healthcare related to technology

-Elaborate how technology can improve health outcomes in your population

**## DiabetesType11.docx**

Diabetes Type 1: Improving Outcomes through Technology

Student

Instructor

University affiliation

Class Name

Date

**Diabetes Type 1: Improving Outcomes through Technology**

**Introduction**

Children and young adults develop Type 1 diabetes which needs continuous life-long healthcare. The immune system accidentally damages pancreatic beta cells that make insulin which causes insulin to drop below normal levels. Type 2 diabetes normally develops because of unhealthy behaviors yet Type 1 diabetes depends mainly on genetics and surrounding conditions. The world experiences rising numbers of people affected by T1D which now totals 9 million cases. People with T1D need to control their blood sugar levels to avoid developing life-threatening DKA and avoid nerve and heart diseases plus eye problems (Addala et al., 2021). Uncontrolled diabetes causes patients to need frequent hospital visits and eventually becomes disabling. As technology keeps advancing people with diabetes can now receive better treatment options to improve their health and daily life. Advanced digital health solutions such as CGM and insulin pumps alongside digital health technology now help patients manage their diabetes care better.

**Global Burden of Disease Condition**

The global health problem of T1D mainly affects children and teenagers with no age or geographic boundaries. More T1D cases require us to find better ways to provide healthcare services to patients. People with Type 1 Diabetes need insulin treatment to survive since their condition differs from Type 2 which responds to lifestyle changes. The body's immune system starts hurting the pancreas for no clear reasons with T1D and this disease develops unpredictably (Agarwal et al., 2021).

**Signs and Symptoms**

T1D develops when patients show hyperglycemic effects such as intense thirst (polydipsia), heavy urination (polyuria), unexpected weight loss, persistent tiredness, and vision problems. Young people typically display changes in their moods and do not pay attention well during class time. When T1D remains untreated it turns into DKA which becomes an emergency condition that causes strong nausea and vomiting plus stomach pain alongside sweet breath smells and confusion before putting a patient into a coma. Patients need urgent medical care at the hospital to treat DKA.

**Diagnosis and Treatment**

Doctors identify Type 1 diabetes using multiple blood measurements including how patients handle fasting glucose levels and HbA1c alongside tests for autoantibodies linked to diabetes. When people with diabetes experience symptoms and their blood sugar levels exceed 200 mg/dL on a random test it signifies they have the condition. Patients who receive their T1D diagnosis need permanent insulin treatment either through multiple daily injections or continuous subcutaneous insulin infusions pumping (CGMS) systems. Beside insulin treatment T1D management needs patients to track their diet habits and activities plus perform regular glucose tests to prevent dangerous blood sugar levels. Our aim is to manage blood glucose values at certain levels to decrease the chances of developing diabetes complications.

**Technology and Healthcare**

Technology has transformed how healthcare manages chronic diseases across all settings of care. Modern medical devices such as CGM systems insulin pumps and artificial pancreas systems revolutionize how healthcare professionals handle diabetes. Our new technologies show blood sugar levels in real time while controlling insulin actions and sharing performance results. New digital healthcare tools help patients talk to doctors online in real time which makes them visit hospitals less often.

**Improving Health Outcomes through Technology**

New technology enhances T1D management by showing blood sugar data in real time plus alerts patients before extreme glucose changes and decreases their risk of severe hypoglycemia and hyperglycemia. The healthcare provider monitors patient glucose data from a distance and customizes health care approach based on results. The diabetes management mobile apps allow patients to measure their food carbs while recording their insulin and exercise habits. Researchers test how machine learning and artificial intelligence technologies can identify future blood sugar patterns and suggest custom insulin changes.

**Chosen Evidence-Based Technology Use in Disease Management**

Continuous Glucose Monitoring (CGM) technology has emerged as an important tool to manage Type 1 diabetes better. CGMs show blood sugar numbers right now and help detect dangerous blood sugar drops and rises which enable better T1D handling. With CGMs patients avoid frequent fingerprick blood tests because these devices directly monitor glucose levels from beneath the skin.

**Benefits of CGM Use**

Research proves that continuous glucose monitoring (CGM) systems lower HbA1c readings while making glucose levels more steady and lowering how often severe hypoglycemia happens (Majidi et al., 2021). CGMs help patients better control their condition while lowering diabetes stress and enhancing their lifestyle. CGM systems help patients spot dangerous blood sugar levels so they can start treatment at once to avoid health problems. Shoppers today can connect their CGMs to smartphone applications which show their blood sugar levels in real time and let them pass results to doctors for better care. CGMs help parents monitor their children's blood sugar levels from any location which brings peace to both parties.

**Challenges of CGM Use**

While CGM offers many benefits new users encounter substantial issues including high expense and limited availability plus short sensor life. Insurance companies do not support CGM payment which becomes expensive for many patients to afford. Some patients find sensor placement uncomfortable and deal with too many data points that cause them to get tired of using the system. The device shows imprecise measurements when the user has incorrect hydration levels or improper device setup steps. Technology enhancements create better CGMs that are easier to use and less expensive (Eberle & Stichling, 2021). Modern CGM systems let users wear sensors for longer periods because both sensor and pump connect automatically during factory calibration.

**Conclusion**

Technology integration in diabetes care brings better healthcare results especially to Type 1 Diabetes patients. Continuous Glucose Monitoring technology leads to improved blood sugar control and reduced health problems while making life for patients much better. The future of diabetes treatment depends on new developments in digital health through artificial pancreas technology which regulates insulin delivery based on live glucose measurements. Healthcare technology advances require us to make patient resources available at reasonable costs while teaching people how to use these tools effectively. Medical groups and government agencies must work together with research experts to provide people with new diabetes control methods. Using technology systems can help healthcare teams deliver better care to people with T1D which leads to better health results and enhances their daily life.

References

Addala, A., Auzanneau, M., Miller, K., Maier, W., Foster, N., Kapellen, T., … & Holl, R. W. (2021). A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: a transatlantic comparison.
_Diabetes Care_,
_44_(1), 133-140.
[https://doi.org/10.2337/dc20-0257](https://doi.org/10.2337/dc20-0257)

Agarwal, S., Schechter, C., Gonzalez, J., & Long, J. A. (2021). Racial–ethnic disparities in diabetes technology use among young adults with type 1 diabetes.
_Diabetes Technology & Therapeutics_,
_23_(4), 306-313.
[https://doi.org/10.1089/dia.2020.0338](https://doi.org/10.1089/dia.2020.0338)

Eberle, C., & Stichling, S. (2021). Clinical improvements by telemedicine interventions managing type 1 and type 2 diabetes: systematic meta-review.
_Journal of medical Internet research_,
_23_(2), e23244.
[https://doi.org/10.2196/23244](https://doi.org/10.2196/23244)

Majidi, S., Ebekozien, O., Noor, N., Lyons, S. K., McDonough, R., Gandhi, K., … & T1D Exchange Quality Improvement Collaborative Study Group. (2021). Inequities in health outcomes in children and adults with type 1 diabetes: data from the T1D Exchange Quality Improvement Collaborative.
_Clinical Diabetes_,
_39_(3), 278-283.
[https://doi.org/10.2337/cd21-0028](https://doi.org/10.2337/cd21-0028)

**## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx**

**This is the second part and professor feedback of first part**

**Feedback** make sure to use an appropriate tool on week 12 when evaluating the outcomes,

**Chosen Evidence-Based Technology Use in Disease or Risk Factor**

-Describe and summarize the evidence-based technology identified that has been shown to improve the condition or Risk Factor for your patient population chosen.

-Compare and contrast the positives and negatives of using this technology use chosen.

**Conclusion**

-Recap points discussed in the paper

-Importance of advancements in technology

**Signature Assignment. Submit the complete paper including the conclusion**

Completion requirements

**Opened:** Monday, March 24, 2025, 11:00 AM

**Due:** Sunday, March 30, 2025, 11:00 PM

Full description of the assignment is included at the end of the syllabus.
In this section the students needs to submit a complete assignment. Which includes: Introduction, Body and Conclusion.

Introduction:

**Introduction:**

Brief overview of the health of the population chosen

-Introduce the global burden of disease OR risk factor chosen

-Importance of improving the condition and its impact on quality of life

**Body of the Paper**

**Global Burden of Disease Condition/Risk Factor**

-Describe the disease OR risk factor chosen

-What signs/symptoms are identified in the patient that can be found?

-How is it diagnosed and treated?

**Technology and Healthcare**

-Describe the paradigm shift in healthcare related to technology

-Elaborate how technology can improve health outcomes in your population

**## DiabetesType11.docx**

Diabetes Type 1: Improving Outcomes through Technology

Student

Instructor

University affiliation

Class Name

Date

**Diabetes Type 1: Improving Outcomes through Technology**

**Introduction**

Children and young adults develop Type 1 diabetes which needs continuous life-long healthcare. The immune system accidentally damages pancreatic beta cells that make insulin which causes insulin to drop below normal levels. Type 2 diabetes normally develops because of unhealthy behaviors yet Type 1 diabetes depends mainly on genetics and surrounding conditions. The world experiences rising numbers of people affected by T1D which now totals 9 million cases. People with T1D need to control their blood sugar levels to avoid developing life-threatening DKA and avoid nerve and heart diseases plus eye problems (Addala et al., 2021). Uncontrolled diabetes causes patients to need frequent hospital visits and eventually becomes disabling. As technology keeps advancing people with diabetes can now receive better treatment options to improve their health and daily life. Advanced digital health solutions such as CGM and insulin pumps alongside digital health technology now help patients manage their diabetes care better.

**Global Burden of Disease Condition**

The global health problem of T1D mainly affects children and teenagers with no age or geographic boundaries. More T1D cases require us to find better ways to provide healthcare services to patients. People with Type 1 Diabetes need insulin treatment to survive since their condition differs from Type 2 which responds to lifestyle changes. The body's immune system starts hurting the pancreas for no clear reasons with T1D and this disease develops unpredictably (Agarwal et al., 2021).

**Signs and Symptoms**

T1D develops when patients show hyperglycemic effects such as intense thirst (polydipsia), heavy urination (polyuria), unexpected weight loss, persistent tiredness, and vision problems. Young people typically display changes in their moods and do not pay attention well during class time. When T1D remains untreated it turns into DKA which becomes an emergency condition that causes strong nausea and vomiting plus stomach pain alongside sweet breath smells and confusion before putting a patient into a coma. Patients need urgent medical care at the hospital to treat DKA.

**Diagnosis and Treatment**

Doctors identify Type 1 diabetes using multiple blood measurements including how patients handle fasting glucose levels and HbA1c alongside tests for autoantibodies linked to diabetes. When people with diabetes experience symptoms and their blood sugar levels exceed 200 mg/dL on a random test it signifies they have the condition. Patients who receive their T1D diagnosis need permanent insulin treatment either through multiple daily injections or continuous subcutaneous insulin infusions pumping (CGMS) systems. Beside insulin treatment T1D management needs patients to track their diet habits and activities plus perform regular glucose tests to prevent dangerous blood sugar levels. Our aim is to manage blood glucose values at certain levels to decrease the chances of developing diabetes complications.

**Technology and Healthcare**

Technology has transformed how healthcare manages chronic diseases across all settings of care. Modern medical devices such as CGM systems insulin pumps and artificial pancreas systems revolutionize how healthcare professionals handle diabetes. Our new technologies show blood sugar levels in real time while controlling insulin actions and sharing performance results. New digital healthcare tools help patients talk to doctors online in real time which makes them visit hospitals less often.

**Improving Health Outcomes through Technology**

New technology enhances T1D management by showing blood sugar data in real time plus alerts patients before extreme glucose changes and decreases their risk of severe hypoglycemia and hyperglycemia. The healthcare provider monitors patient glucose data from a distance and customizes health care approach based on results. The diabetes management mobile apps allow patients to measure their food carbs while recording their insulin and exercise habits. Researchers test how machine learning and artificial intelligence technologies can identify future blood sugar patterns and suggest custom insulin changes.

**Chosen Evidence-Based Technology Use in Disease Management**

Continuous Glucose Monitoring (CGM) technology has emerged as an important tool to manage Type 1 diabetes better. CGMs show blood sugar numbers right now and help detect dangerous blood sugar drops and rises which enable better T1D handling. With CGMs patients avoid frequent fingerprick blood tests because these devices directly monitor glucose levels from beneath the skin.

**Benefits of CGM Use**

Research proves that continuous glucose monitoring (CGM) systems lower HbA1c readings while making glucose levels more steady and lowering how often severe hypoglycemia happens (Majidi et al., 2021). CGMs help patients better control their condition while lowering diabetes stress and enhancing their lifestyle. CGM systems help patients spot dangerous blood sugar levels so they can start treatment at once to avoid health problems. Shoppers today can connect their CGMs to smartphone applications which show their blood sugar levels in real time and let them pass results to doctors for better care. CGMs help parents monitor their children's blood sugar levels from any location which brings peace to both parties.

**Challenges of CGM Use**

While CGM offers many benefits new users encounter substantial issues including high expense and limited availability plus short sensor life. Insurance companies do not support CGM payment which becomes expensive for many patients to afford. Some patients find sensor placement uncomfortable and deal with too many data points that cause them to get tired of using the system. The device shows imprecise measurements when the user has incorrect hydration levels or improper device setup steps. Technology enhancements create better CGMs that are easier to use and less expensive (Eberle & Stichling, 2021). Modern CGM systems let users wear sensors for longer periods because both sensor and pump connect automatically during factory calibration.

**Conclusion**

Technology integration in diabetes care brings better healthcare results especially to Type 1 Diabetes patients. Continuous Glucose Monitoring technology leads to improved blood sugar control and reduced health problems while making life for patients much better. The future of diabetes treatment depends on new developments in digital health through artificial pancreas technology which regulates insulin delivery based on live glucose measurements. Healthcare technology advances require us to make patient resources available at reasonable costs while teaching people how to use these tools effectively. Medical groups and government agencies must work together with research experts to provide people with new diabetes control methods. Using technology systems can help healthcare teams deliver better care to people with T1D which leads to better health results and enhances their daily life.

References

Addala, A., Auzanneau, M., Miller, K., Maier, W., Foster, N., Kapellen, T., … & Holl, R. W. (2021). A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: a transatlantic comparison.
_Diabetes Care_,
_44_(1), 133-140.
[https://doi.org/10.2337/dc20-0257](https://doi.org/10.2337/dc20-0257)

Agarwal, S., Schechter, C., Gonzalez, J., & Long, J. A. (2021). Racial–ethnic disparities in diabetes technology use among young adults with type 1 diabetes.
_Diabetes Technology & Therapeutics_,
_23_(4), 306-313.
[https://doi.org/10.1089/dia.2020.0338](https://doi.org/10.1089/dia.2020.0338)

Eberle, C., & Stichling, S. (2021). Clinical improvements by telemedicine interventions managing type 1 and type 2 diabetes: systematic meta-review.
_Journal of medical Internet research_,
_23_(2), e23244.
[https://doi.org/10.2196/23244](https://doi.org/10.2196/23244)

Majidi, S., Ebekozien, O., Noor, N., Lyons, S. K., McDonough, R., Gandhi, K., … & T1D Exchange Quality Improvement Collaborative Study Group. (2021). Inequities in health outcomes in children and adults with type 1 diabetes: data from the T1D Exchange Quality Improvement Collaborative.
_Clinical Diabetes_,
_39_(3), 278-283.
[https://doi.org/10.2337/cd21-0028](https://doi.org/10.2337/cd21-0028)

November 5, 2026
[Solved] Math

✓ Verified Academic Solution Available

Executive Solution Overview

[>Geometry homework help](https://www.sweetstudy.com/fields/mathematics-geometry) math – 2 years ago

Instant Solution Download
$6.99

Immediate access to the full model answer, formatted citations, and rubric breakdown.

Need a Fresh Custom Paper?

Have this question answered from scratch according to your specific instructions and deadline.
Order on TutorsGallery →

Assignment Prompt & Instructions

[>Geometry homework help](https://www.sweetstudy.com/fields/mathematics-geometry)

math

– 2 years ago

November 5, 2026
[Solved] Week 4 discussions

✓ Verified Academic Solution Available

Executive Solution Overview

APA format Due in 7 HOURS – 2 years ago **files (1)** – ## week4pedsdiscussion222222.docx **## week4pedsdiscussion222222.docx** Minimum 1 paragraph per question. Can use bullet points if asking question Mark is a 5-year-old male who was brought into the clinic today for a well-child exam. His mother…

Instant Solution Download
$6.99

Immediate access to the full model answer, formatted citations, and rubric breakdown.

Need a Fresh Custom Paper?

Have this question answered from scratch according to your specific instructions and deadline.
Order on TutorsGallery →

Assignment Prompt & Instructions

APA format

Due in 7 HOURS

– 2 years ago

**files (1)**

– ## week4pedsdiscussion222222.docx

**## week4pedsdiscussion222222.docx**

Minimum 1 paragraph per question. Can use bullet points if asking question

Mark is a 5-year-old male who was brought into the clinic today for a well-child exam. His mother reports that she is concerned that Mark wets his bed at night 3 to 4 times per week. She is at her wit’s end and does not know what to do.

· What does the APRN need to know about Mark’s condition?

· What are some of the possible causes for Mark’s condition?

· What strategies should the APRN share with Mark’s mother to help him stay dry at night?

APA format

**## week4pedsdiscussion222222.docx**

Minimum 1 paragraph per question. Can use bullet points if asking question

Mark is a 5-year-old male who was brought into the clinic today for a well-child exam. His mother reports that she is concerned that Mark wets his bed at night 3 to 4 times per week. She is at her wit’s end and does not know what to do.

· What does the APRN need to know about Mark’s condition?

· What are some of the possible causes for Mark’s condition?

· What strategies should the APRN share with Mark’s mother to help him stay dry at night?

APA format

November 5, 2026
[Solved] Asssigment

✓ Verified Academic Solution Available

Executive Solution Overview

– 2 years ago **files (2)** – ## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx – ## RoleDevelopmentinFamilyPracticeRDS.ST1.docx **## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx** **This is the second part and professor feedback of first part** **Feedback** Good discussion make …

Instant Solution Download
$6.99

Immediate access to the full model answer, formatted citations, and rubric breakdown.

Need a Fresh Custom Paper?

Have this question answered from scratch according to your specific instructions and deadline.
Order on TutorsGallery →

Assignment Prompt & Instructions

– 2 years ago

**files (2)**

– ## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx

– ## RoleDevelopmentinFamilyPracticeRDS.ST1.docx

**## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx**

**This is the second part and professor feedback of first part**

**Feedback** Good discussion make sure to use an appropriate tool on week 12 when evaluating the outcomes, specially using telemedicine

**Chosen Evidence-Based Technology Use in Disease or Risk Factor**

-Describe and summarize the evidence-based technology identified that has been shown to improve the condition or Risk Factor for your patient population chosen.

-Compare and contrast the positives and negatives of using this technology use chosen.

**Conclusion**

-Recap points discussed in the paper

-Importance of advancements in technology

**Signature Assignment. Submit the complete paper including the conclusion**

Completion requirements

**Opened:** Monday, March 24, 2025, 11:00 AM

**Due:** Sunday, March 30, 2025, 11:00 PM

Full description of the assignment is included at the end of the syllabus.
In this section the students needs to submit a complete assignment. Which includes: Introduction, Body and Conclusion.

Introduction:

**Introduction:**

Brief overview of the health of the population chosen

-Introduce the global burden of disease OR risk factor chosen

-Importance of improving the condition and its impact on quality of life

**Body of the Paper**

**Global Burden of Disease Condition/Risk Factor**

-Describe the disease OR risk factor chosen

-What signs/symptoms are identified in the patient that can be found?

-How is it diagnosed and treated?

**Technology and Healthcare**

-Describe the paradigm shift in healthcare related to technology

-Elaborate how technology can improve health outcomes in your population

**## RoleDevelopmentinFamilyPracticeRDS.ST1.docx**

1

**Role Development in Family Practice: Clinical Integration**

Student’s name

Name of institution

Course name and number

Instructor’s name

Due date

**Role Development in Family Practice: Clinical Integration**

Neonatal illness is an area of continued concern in international pediatrics, with numerous conditions causing rising rates of morbidity and mortality. One of these is neonatal respiratory distress syndrome, an incredibly debilitating illness in preterm neonates due to decreased production of surfactants. This illness results in acute breathing difficulty that, in most instances, warrants immediate specialized attention. RDS has an immense worldwide burden, most especially in developing nations where advanced neonatology facilities are not readily accessible According to World Health Organization reports, preterm birth complications, including RDS, contribute to nearly 35% of global neonatal deaths among the 2.5 million deaths documented in the year 2021. Additionally, the condition RDS occurs in about 1% of all live births, along with affecting 55% of preterm infants born at less than thirty-six weeks. Improved neonatal management and better neonatal diagnosis can significantly reduce neonatal mortality and subsequent complication rates, such as chronic pulmonary disease. The application of evidenced-based technologies in the form of point-of-care ultrasound and telemedicine is an opportunity to diagnose neonates better early in life to direct therapy and provide specialized therapy to remote populations. Applying these technologies is necessary to provide better outcomes for neonates with limited facilities in neonatal intensive units. Healthcare providers can accomplish this by providing timely interventions in neonates with these conditions through these technologies to avoid subsequent complications while improving the family's overall quality of life.

**Neonatal Respiratory Distress Syndrome**

Neonatal respiratory distress syndrome exists as a widespread, serious issue that affects premature infants born earlier than 38 weeks of gestational age. It comes from a deficiency of pulmonary surfactant that produces the condition, which results in high alveolar surface tension and prevents alveolar capacity to exchange gases. An undeveloped amount of surfactant during lung expansion can cause hypoxia, which afterward triggers respiratory failure in newborns. The condition also shows its initial symptoms when the newborn is between zero to a few hours old (Ying et al., 2021). The clinical features include rapid breathing, also known as tachypnea, combined with nasal flaring and grunting, chest retractions, and blue-colored skin, indicating hypoxia. Medical staff primarily make diagnoses of this condition based on clinical evidence alongside blood gas testing and chest X-ray imaging for detecting a distinctive pattern, and continuous positive airway pressure combined with ventilator support receives priority in treatments along with surfactant replacement therapy for promoting lung function.

**Technology and Healthcare**

Technology role has increased neonatal survival rates and reduced related morbidities in diseases like RDS in neonates. Advances in point-of-care ultrasound and telemedicine have provided neonatologists with additional capabilities to treat patients better in remote areas where neonatologists have limited accessibility (Padovani et al., 2023). Telemedicine has introduced remote evaluation, diagnosis, and management of neonates by healthcare providers, irrespective of physical location. It is particularly beneficial in areas where neonatologists and respiratory therapists have limited accessibility. Similarly, POCUS provides in-bed scanning to obtain instant, accurate results regarding pathologies in the lungs in the absence of radiographic exposure. All these tools accelerate early identification and management to achieve better outcomes in neonates and reduce mortality rates.

**Chosen Evidence-Based Technology**

The outcomes of neonatal RDS can be improved significantly by applying telemedicine in resource-limited settings. Neonatologists can support healthcare providers in rural or underserved units through live video conferencing to manage RDS appropriately and promptly. Telemedicine allows remote observation of neonates who have been ventilated to monitor outcomes and prevent unnecessary neonatal transfers while optimizing management programs to prevent complication rates. Telemedicine has been applied in neonatology with notable outcomes. Research has confirmed that telemedicine reduces unnecessary neonatal transfers by allowing remote specialist visits to prevent healthcare expenditures while improving specialist accessibility (Chuo et al., 2022). Telemedicine has been employed to empower parents through improved education to detect early symptoms of respiratory distress and initiate appropriate management in time. However, telemedicine is not free of certain limitations. Low penetration of the internet in specific locations can negate its potential. Additionally, regulatory and legal impediments to the widespread use of telemedicine can arise in certain domains regarding data privacy and security. However, telemedicine is an attractive means to improve neonatal outcomes in underserved populations where specialized neonatal facilities are not accessible.

Similarly, another notable technological development is point-of-care ultrasound, which enhances neonatal management and diagnosis. Historically, RDS has been diagnosed by chest X-ray; however, POCUS provides an alternative by providing an instant, cheaper, and safer modality. Facilitating in situ visualization in real time of pulmonary pathology enables physicians to decide upon lung aeration status, detect pneumothorax, among others, among neonates, and guide management decisions without exposing neonates to the use of ionizing radiation (Gjesteby et al., 2022). The advantages of POCUS in neonatal RDS management include that it can quickly evaluate patients, enabling early treatment and diagnosis. It is an economical and portable imaging modality that can be employed in neonatal ICU departments and institutions with fewer resources. Research has confirmed that it is diagnostic in capacity to identify and can be employed by trained individuals with minimal additional training. However, despite its advantages, neonatology has limitations when applying POCUS. Interpretation is operator-dependent in experience and expertise, and mastery has a steep learning curve. It is not an overall pulmonary functional evaluation and should always be employed in concert with clinical evaluation and additional diagnostic methods.

**Conclusion**

Neonatal respiratory distress syndrome exists as a worldwide concern affecting all preterm babies. Early diagnosis, together with effective management, becomes essential since it affects neonatal mortality rates while impacting long-term outcomes. Respiratory disease outcomes show potential for improvement with point-of-care ultrasound technology and telemedicine through specialized care access, diagnosis capabilities, and correct treatment approaches. Through telemedicine technology, parents can access remote medical appointments to receive prompt care while preventing unsafe patient transports. At the same time, point-of-care ultrasound increases the ability to evaluate pulmonary pathologies within the bed where appropriate interventions can be made promptly. The potential drawbacks of these tools do not outweigh the advantages in optimizing neonatal patient outcomes. Medical progress constitutes a crucial element for decreasing the healthcare inequalities experienced by neonates, particularly in neonatology. Healthcare providers should, therefore, adopt these advances to reduce neonatal death rates and deliver better future outcomes for patients who have RDS.

**References**

Chuo, J., Makkar, A., Machut, K., Zenge, J., Jawahar Jagarapu, Abeer Azzuqa, & Savani, R. C. (2022). Telemedicine across the continuum of neonatal-perinatal care.
_Seminars in Fetal and Neonatal Medicine_,
_27_(5), 101398–101398. https://doi.org/10.1016/j.siny.2022.101398

Gjesteby, L. A., Pare, J. R., & Brattain, L. J. (2022). Ultrasound for the Emergency Department and Prehospital Care.
_Engineering and Medicine in Extreme Environments_, 209–234. https://doi.org/10.1007/978-3-030-96921-9_11

Padovani, P., Singh, Y., Pass, R. H., Vasile, C. M., Nield, L. E., & Baruteau, A.-E. (2023). E-Health: A Game Changer in Fetal and Neonatal Cardiology?
_Journal of Clinical Medicine_,
_12_(21), 6865. https://doi.org/10.3390/jcm12216865

Ying, Q., You, X., Luo, F., & Wang, J. (2021). Maternal-Neonatal Serum Albumin Level and Neonatal Respiratory Distress Syndrome in Late-Preterm Infants.
_Frontiers in Pediatrics_,
_9_. https://doi.org/10.3389/fped.2021.666934

**## RoleDevelopmentinFamilyPracticeRDS.ST1.docx**

1

**Role Development in Family Practice: Clinical Integration**

Student’s name

Name of institution

Course name and number

Instructor’s name

Due date

**Role Development in Family Practice: Clinical Integration**

Neonatal illness is an area of continued concern in international pediatrics, with numerous conditions causing rising rates of morbidity and mortality. One of these is neonatal respiratory distress syndrome, an incredibly debilitating illness in preterm neonates due to decreased production of surfactants. This illness results in acute breathing difficulty that, in most instances, warrants immediate specialized attention. RDS has an immense worldwide burden, most especially in developing nations where advanced neonatology facilities are not readily accessible According to World Health Organization reports, preterm birth complications, including RDS, contribute to nearly 35% of global neonatal deaths among the 2.5 million deaths documented in the year 2021. Additionally, the condition RDS occurs in about 1% of all live births, along with affecting 55% of preterm infants born at less than thirty-six weeks. Improved neonatal management and better neonatal diagnosis can significantly reduce neonatal mortality and subsequent complication rates, such as chronic pulmonary disease. The application of evidenced-based technologies in the form of point-of-care ultrasound and telemedicine is an opportunity to diagnose neonates better early in life to direct therapy and provide specialized therapy to remote populations. Applying these technologies is necessary to provide better outcomes for neonates with limited facilities in neonatal intensive units. Healthcare providers can accomplish this by providing timely interventions in neonates with these conditions through these technologies to avoid subsequent complications while improving the family's overall quality of life.

**Neonatal Respiratory Distress Syndrome**

Neonatal respiratory distress syndrome exists as a widespread, serious issue that affects premature infants born earlier than 38 weeks of gestational age. It comes from a deficiency of pulmonary surfactant that produces the condition, which results in high alveolar surface tension and prevents alveolar capacity to exchange gases. An undeveloped amount of surfactant during lung expansion can cause hypoxia, which afterward triggers respiratory failure in newborns. The condition also shows its initial symptoms when the newborn is between zero to a few hours old (Ying et al., 2021). The clinical features include rapid breathing, also known as tachypnea, combined with nasal flaring and grunting, chest retractions, and blue-colored skin, indicating hypoxia. Medical staff primarily make diagnoses of this condition based on clinical evidence alongside blood gas testing and chest X-ray imaging for detecting a distinctive pattern, and continuous positive airway pressure combined with ventilator support receives priority in treatments along with surfactant replacement therapy for promoting lung function.

**Technology and Healthcare**

Technology role has increased neonatal survival rates and reduced related morbidities in diseases like RDS in neonates. Advances in point-of-care ultrasound and telemedicine have provided neonatologists with additional capabilities to treat patients better in remote areas where neonatologists have limited accessibility (Padovani et al., 2023). Telemedicine has introduced remote evaluation, diagnosis, and management of neonates by healthcare providers, irrespective of physical location. It is particularly beneficial in areas where neonatologists and respiratory therapists have limited accessibility. Similarly, POCUS provides in-bed scanning to obtain instant, accurate results regarding pathologies in the lungs in the absence of radiographic exposure. All these tools accelerate early identification and management to achieve better outcomes in neonates and reduce mortality rates.

**Chosen Evidence-Based Technology**

The outcomes of neonatal RDS can be improved significantly by applying telemedicine in resource-limited settings. Neonatologists can support healthcare providers in rural or underserved units through live video conferencing to manage RDS appropriately and promptly. Telemedicine allows remote observation of neonates who have been ventilated to monitor outcomes and prevent unnecessary neonatal transfers while optimizing management programs to prevent complication rates. Telemedicine has been applied in neonatology with notable outcomes. Research has confirmed that telemedicine reduces unnecessary neonatal transfers by allowing remote specialist visits to prevent healthcare expenditures while improving specialist accessibility (Chuo et al., 2022). Telemedicine has been employed to empower parents through improved education to detect early symptoms of respiratory distress and initiate appropriate management in time. However, telemedicine is not free of certain limitations. Low penetration of the internet in specific locations can negate its potential. Additionally, regulatory and legal impediments to the widespread use of telemedicine can arise in certain domains regarding data privacy and security. However, telemedicine is an attractive means to improve neonatal outcomes in underserved populations where specialized neonatal facilities are not accessible.

Similarly, another notable technological development is point-of-care ultrasound, which enhances neonatal management and diagnosis. Historically, RDS has been diagnosed by chest X-ray; however, POCUS provides an alternative by providing an instant, cheaper, and safer modality. Facilitating in situ visualization in real time of pulmonary pathology enables physicians to decide upon lung aeration status, detect pneumothorax, among others, among neonates, and guide management decisions without exposing neonates to the use of ionizing radiation (Gjesteby et al., 2022). The advantages of POCUS in neonatal RDS management include that it can quickly evaluate patients, enabling early treatment and diagnosis. It is an economical and portable imaging modality that can be employed in neonatal ICU departments and institutions with fewer resources. Research has confirmed that it is diagnostic in capacity to identify and can be employed by trained individuals with minimal additional training. However, despite its advantages, neonatology has limitations when applying POCUS. Interpretation is operator-dependent in experience and expertise, and mastery has a steep learning curve. It is not an overall pulmonary functional evaluation and should always be employed in concert with clinical evaluation and additional diagnostic methods.

**Conclusion**

Neonatal respiratory distress syndrome exists as a worldwide concern affecting all preterm babies. Early diagnosis, together with effective management, becomes essential since it affects neonatal mortality rates while impacting long-term outcomes. Respiratory disease outcomes show potential for improvement with point-of-care ultrasound technology and telemedicine through specialized care access, diagnosis capabilities, and correct treatment approaches. Through telemedicine technology, parents can access remote medical appointments to receive prompt care while preventing unsafe patient transports. At the same time, point-of-care ultrasound increases the ability to evaluate pulmonary pathologies within the bed where appropriate interventions can be made promptly. The potential drawbacks of these tools do not outweigh the advantages in optimizing neonatal patient outcomes. Medical progress constitutes a crucial element for decreasing the healthcare inequalities experienced by neonates, particularly in neonatology. Healthcare providers should, therefore, adopt these advances to reduce neonatal death rates and deliver better future outcomes for patients who have RDS.

**References**

Chuo, J., Makkar, A., Machut, K., Zenge, J., Jawahar Jagarapu, Abeer Azzuqa, & Savani, R. C. (2022). Telemedicine across the continuum of neonatal-perinatal care.
_Seminars in Fetal and Neonatal Medicine_,
_27_(5), 101398–101398. https://doi.org/10.1016/j.siny.2022.101398

Gjesteby, L. A., Pare, J. R., & Brattain, L. J. (2022). Ultrasound for the Emergency Department and Prehospital Care.
_Engineering and Medicine in Extreme Environments_, 209–234. https://doi.org/10.1007/978-3-030-96921-9_11

Padovani, P., Singh, Y., Pass, R. H., Vasile, C. M., Nield, L. E., & Baruteau, A.-E. (2023). E-Health: A Game Changer in Fetal and Neonatal Cardiology?
_Journal of Clinical Medicine_,
_12_(21), 6865. https://doi.org/10.3390/jcm12216865

Ying, Q., You, X., Luo, F., & Wang, J. (2021). Maternal-Neonatal Serum Albumin Level and Neonatal Respiratory Distress Syndrome in Late-Preterm Infants.
_Frontiers in Pediatrics_,
_9_. https://doi.org/10.3389/fped.2021.666934

**## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx**

**This is the second part and professor feedback of first part**

**Feedback** Good discussion make sure to use an appropriate tool on week 12 when evaluating the outcomes, specially using telemedicine

**Chosen Evidence-Based Technology Use in Disease or Risk Factor**

-Describe and summarize the evidence-based technology identified that has been shown to improve the condition or Risk Factor for your patient population chosen.

-Compare and contrast the positives and negatives of using this technology use chosen.

**Conclusion**

-Recap points discussed in the paper

-Importance of advancements in technology

**Signature Assignment. Submit the complete paper including the conclusion**

Completion requirements

**Opened:** Monday, March 24, 2025, 11:00 AM

**Due:** Sunday, March 30, 2025, 11:00 PM

Full description of the assignment is included at the end of the syllabus.
In this section the students needs to submit a complete assignment. Which includes: Introduction, Body and Conclusion.

Introduction:

**Introduction:**

Brief overview of the health of the population chosen

-Introduce the global burden of disease OR risk factor chosen

-Importance of improving the condition and its impact on quality of life

**Body of the Paper**

**Global Burden of Disease Condition/Risk Factor**

-Describe the disease OR risk factor chosen

-What signs/symptoms are identified in the patient that can be found?

-How is it diagnosed and treated?

**Technology and Healthcare**

-Describe the paradigm shift in healthcare related to technology

-Elaborate how technology can improve health outcomes in your population

**## RoleDevelopmentinFamilyPracticeRDS.ST1.docx**

1

**Role Development in Family Practice: Clinical Integration**

Student’s name

Name of institution

Course name and number

Instructor’s name

Due date

**Role Development in Family Practice: Clinical Integration**

Neonatal illness is an area of continued concern in international pediatrics, with numerous conditions causing rising rates of morbidity and mortality. One of these is neonatal respiratory distress syndrome, an incredibly debilitating illness in preterm neonates due to decreased production of surfactants. This illness results in acute breathing difficulty that, in most instances, warrants immediate specialized attention. RDS has an immense worldwide burden, most especially in developing nations where advanced neonatology facilities are not readily accessible According to World Health Organization reports, preterm birth complications, including RDS, contribute to nearly 35% of global neonatal deaths among the 2.5 million deaths documented in the year 2021. Additionally, the condition RDS occurs in about 1% of all live births, along with affecting 55% of preterm infants born at less than thirty-six weeks. Improved neonatal management and better neonatal diagnosis can significantly reduce neonatal mortality and subsequent complication rates, such as chronic pulmonary disease. The application of evidenced-based technologies in the form of point-of-care ultrasound and telemedicine is an opportunity to diagnose neonates better early in life to direct therapy and provide specialized therapy to remote populations. Applying these technologies is necessary to provide better outcomes for neonates with limited facilities in neonatal intensive units. Healthcare providers can accomplish this by providing timely interventions in neonates with these conditions through these technologies to avoid subsequent complications while improving the family's overall quality of life.

**Neonatal Respiratory Distress Syndrome**

Neonatal respiratory distress syndrome exists as a widespread, serious issue that affects premature infants born earlier than 38 weeks of gestational age. It comes from a deficiency of pulmonary surfactant that produces the condition, which results in high alveolar surface tension and prevents alveolar capacity to exchange gases. An undeveloped amount of surfactant during lung expansion can cause hypoxia, which afterward triggers respiratory failure in newborns. The condition also shows its initial symptoms when the newborn is between zero to a few hours old (Ying et al., 2021). The clinical features include rapid breathing, also known as tachypnea, combined with nasal flaring and grunting, chest retractions, and blue-colored skin, indicating hypoxia. Medical staff primarily make diagnoses of this condition based on clinical evidence alongside blood gas testing and chest X-ray imaging for detecting a distinctive pattern, and continuous positive airway pressure combined with ventilator support receives priority in treatments along with surfactant replacement therapy for promoting lung function.

**Technology and Healthcare**

Technology role has increased neonatal survival rates and reduced related morbidities in diseases like RDS in neonates. Advances in point-of-care ultrasound and telemedicine have provided neonatologists with additional capabilities to treat patients better in remote areas where neonatologists have limited accessibility (Padovani et al., 2023). Telemedicine has introduced remote evaluation, diagnosis, and management of neonates by healthcare providers, irrespective of physical location. It is particularly beneficial in areas where neonatologists and respiratory therapists have limited accessibility. Similarly, POCUS provides in-bed scanning to obtain instant, accurate results regarding pathologies in the lungs in the absence of radiographic exposure. All these tools accelerate early identification and management to achieve better outcomes in neonates and reduce mortality rates.

**Chosen Evidence-Based Technology**

The outcomes of neonatal RDS can be improved significantly by applying telemedicine in resource-limited settings. Neonatologists can support healthcare providers in rural or underserved units through live video conferencing to manage RDS appropriately and promptly. Telemedicine allows remote observation of neonates who have been ventilated to monitor outcomes and prevent unnecessary neonatal transfers while optimizing management programs to prevent complication rates. Telemedicine has been applied in neonatology with notable outcomes. Research has confirmed that telemedicine reduces unnecessary neonatal transfers by allowing remote specialist visits to prevent healthcare expenditures while improving specialist accessibility (Chuo et al., 2022). Telemedicine has been employed to empower parents through improved education to detect early symptoms of respiratory distress and initiate appropriate management in time. However, telemedicine is not free of certain limitations. Low penetration of the internet in specific locations can negate its potential. Additionally, regulatory and legal impediments to the widespread use of telemedicine can arise in certain domains regarding data privacy and security. However, telemedicine is an attractive means to improve neonatal outcomes in underserved populations where specialized neonatal facilities are not accessible.

Similarly, another notable technological development is point-of-care ultrasound, which enhances neonatal management and diagnosis. Historically, RDS has been diagnosed by chest X-ray; however, POCUS provides an alternative by providing an instant, cheaper, and safer modality. Facilitating in situ visualization in real time of pulmonary pathology enables physicians to decide upon lung aeration status, detect pneumothorax, among others, among neonates, and guide management decisions without exposing neonates to the use of ionizing radiation (Gjesteby et al., 2022). The advantages of POCUS in neonatal RDS management include that it can quickly evaluate patients, enabling early treatment and diagnosis. It is an economical and portable imaging modality that can be employed in neonatal ICU departments and institutions with fewer resources. Research has confirmed that it is diagnostic in capacity to identify and can be employed by trained individuals with minimal additional training. However, despite its advantages, neonatology has limitations when applying POCUS. Interpretation is operator-dependent in experience and expertise, and mastery has a steep learning curve. It is not an overall pulmonary functional evaluation and should always be employed in concert with clinical evaluation and additional diagnostic methods.

**Conclusion**

Neonatal respiratory distress syndrome exists as a worldwide concern affecting all preterm babies. Early diagnosis, together with effective management, becomes essential since it affects neonatal mortality rates while impacting long-term outcomes. Respiratory disease outcomes show potential for improvement with point-of-care ultrasound technology and telemedicine through specialized care access, diagnosis capabilities, and correct treatment approaches. Through telemedicine technology, parents can access remote medical appointments to receive prompt care while preventing unsafe patient transports. At the same time, point-of-care ultrasound increases the ability to evaluate pulmonary pathologies within the bed where appropriate interventions can be made promptly. The potential drawbacks of these tools do not outweigh the advantages in optimizing neonatal patient outcomes. Medical progress constitutes a crucial element for decreasing the healthcare inequalities experienced by neonates, particularly in neonatology. Healthcare providers should, therefore, adopt these advances to reduce neonatal death rates and deliver better future outcomes for patients who have RDS.

**References**

Chuo, J., Makkar, A., Machut, K., Zenge, J., Jawahar Jagarapu, Abeer Azzuqa, & Savani, R. C. (2022). Telemedicine across the continuum of neonatal-perinatal care.
_Seminars in Fetal and Neonatal Medicine_,
_27_(5), 101398–101398. https://doi.org/10.1016/j.siny.2022.101398

Gjesteby, L. A., Pare, J. R., & Brattain, L. J. (2022). Ultrasound for the Emergency Department and Prehospital Care.
_Engineering and Medicine in Extreme Environments_, 209–234. https://doi.org/10.1007/978-3-030-96921-9_11

Padovani, P., Singh, Y., Pass, R. H., Vasile, C. M., Nield, L. E., & Baruteau, A.-E. (2023). E-Health: A Game Changer in Fetal and Neonatal Cardiology?
_Journal of Clinical Medicine_,
_12_(21), 6865. https://doi.org/10.3390/jcm12216865

Ying, Q., You, X., Luo, F., & Wang, J. (2021). Maternal-Neonatal Serum Albumin Level and Neonatal Respiratory Distress Syndrome in Late-Preterm Infants.
_Frontiers in Pediatrics_,
_9_. https://doi.org/10.3389/fped.2021.666934

**## Thisisthesecondpartandprofessorfeedbackoffirstpart.docx**

**This is the second part and professor feedback of first part**

**Feedback** Good discussion make sure to use an appropriate tool on week 12 when evaluating the outcomes, specially using telemedicine

**Chosen Evidence-Based Technology Use in Disease or Risk Factor**

-Describe and summarize the evidence-based technology identified that has been shown to improve the condition or Risk Factor for your patient population chosen.

-Compare and contrast the positives and negatives of using this technology use chosen.

**Conclusion**

-Recap points discussed in the paper

-Importance of advancements in technology

**Signature Assignment. Submit the complete paper including the conclusion**

Completion requirements

**Opened:** Monday, March 24, 2025, 11:00 AM

**Due:** Sunday, March 30, 2025, 11:00 PM

Full description of the assignment is included at the end of the syllabus.
In this section the students needs to submit a complete assignment. Which includes: Introduction, Body and Conclusion.

Introduction:

**Introduction:**

Brief overview of the health of the population chosen

-Introduce the global burden of disease OR risk factor chosen

-Importance of improving the condition and its impact on quality of life

**Body of the Paper**

**Global Burden of Disease Condition/Risk Factor**

-Describe the disease OR risk factor chosen

-What signs/symptoms are identified in the patient that can be found?

-How is it diagnosed and treated?

**Technology and Healthcare**

-Describe the paradigm shift in healthcare related to technology

-Elaborate how technology can improve health outcomes in your population

**## RoleDevelopmentinFamilyPracticeRDS.ST1.docx**

1

**Role Development in Family Practice: Clinical Integration**

Student’s name

Name of institution

Course name and number

Instructor’s name

Due date

**Role Development in Family Practice: Clinical Integration**

Neonatal illness is an area of continued concern in international pediatrics, with numerous conditions causing rising rates of morbidity and mortality. One of these is neonatal respiratory distress syndrome, an incredibly debilitating illness in preterm neonates due to decreased production of surfactants. This illness results in acute breathing difficulty that, in most instances, warrants immediate specialized attention. RDS has an immense worldwide burden, most especially in developing nations where advanced neonatology facilities are not readily accessible According to World Health Organization reports, preterm birth complications, including RDS, contribute to nearly 35% of global neonatal deaths among the 2.5 million deaths documented in the year 2021. Additionally, the condition RDS occurs in about 1% of all live births, along with affecting 55% of preterm infants born at less than thirty-six weeks. Improved neonatal management and better neonatal diagnosis can significantly reduce neonatal mortality and subsequent complication rates, such as chronic pulmonary disease. The application of evidenced-based technologies in the form of point-of-care ultrasound and telemedicine is an opportunity to diagnose neonates better early in life to direct therapy and provide specialized therapy to remote populations. Applying these technologies is necessary to provide better outcomes for neonates with limited facilities in neonatal intensive units. Healthcare providers can accomplish this by providing timely interventions in neonates with these conditions through these technologies to avoid subsequent complications while improving the family's overall quality of life.

**Neonatal Respiratory Distress Syndrome**

Neonatal respiratory distress syndrome exists as a widespread, serious issue that affects premature infants born earlier than 38 weeks of gestational age. It comes from a deficiency of pulmonary surfactant that produces the condition, which results in high alveolar surface tension and prevents alveolar capacity to exchange gases. An undeveloped amount of surfactant during lung expansion can cause hypoxia, which afterward triggers respiratory failure in newborns. The condition also shows its initial symptoms when the newborn is between zero to a few hours old (Ying et al., 2021). The clinical features include rapid breathing, also known as tachypnea, combined with nasal flaring and grunting, chest retractions, and blue-colored skin, indicating hypoxia. Medical staff primarily make diagnoses of this condition based on clinical evidence alongside blood gas testing and chest X-ray imaging for detecting a distinctive pattern, and continuous positive airway pressure combined with ventilator support receives priority in treatments along with surfactant replacement therapy for promoting lung function.

**Technology and Healthcare**

Technology role has increased neonatal survival rates and reduced related morbidities in diseases like RDS in neonates. Advances in point-of-care ultrasound and telemedicine have provided neonatologists with additional capabilities to treat patients better in remote areas where neonatologists have limited accessibility (Padovani et al., 2023). Telemedicine has introduced remote evaluation, diagnosis, and management of neonates by healthcare providers, irrespective of physical location. It is particularly beneficial in areas where neonatologists and respiratory therapists have limited accessibility. Similarly, POCUS provides in-bed scanning to obtain instant, accurate results regarding pathologies in the lungs in the absence of radiographic exposure. All these tools accelerate early identification and management to achieve better outcomes in neonates and reduce mortality rates.

**Chosen Evidence-Based Technology**

The outcomes of neonatal RDS can be improved significantly by applying telemedicine in resource-limited settings. Neonatologists can support healthcare providers in rural or underserved units through live video conferencing to manage RDS appropriately and promptly. Telemedicine allows remote observation of neonates who have been ventilated to monitor outcomes and prevent unnecessary neonatal transfers while optimizing management programs to prevent complication rates. Telemedicine has been applied in neonatology with notable outcomes. Research has confirmed that telemedicine reduces unnecessary neonatal transfers by allowing remote specialist visits to prevent healthcare expenditures while improving specialist accessibility (Chuo et al., 2022). Telemedicine has been employed to empower parents through improved education to detect early symptoms of respiratory distress and initiate appropriate management in time. However, telemedicine is not free of certain limitations. Low penetration of the internet in specific locations can negate its potential. Additionally, regulatory and legal impediments to the widespread use of telemedicine can arise in certain domains regarding data privacy and security. However, telemedicine is an attractive means to improve neonatal outcomes in underserved populations where specialized neonatal facilities are not accessible.

Similarly, another notable technological development is point-of-care ultrasound, which enhances neonatal management and diagnosis. Historically, RDS has been diagnosed by chest X-ray; however, POCUS provides an alternative by providing an instant, cheaper, and safer modality. Facilitating in situ visualization in real time of pulmonary pathology enables physicians to decide upon lung aeration status, detect pneumothorax, among others, among neonates, and guide management decisions without exposing neonates to the use of ionizing radiation (Gjesteby et al., 2022). The advantages of POCUS in neonatal RDS management include that it can quickly evaluate patients, enabling early treatment and diagnosis. It is an economical and portable imaging modality that can be employed in neonatal ICU departments and institutions with fewer resources. Research has confirmed that it is diagnostic in capacity to identify and can be employed by trained individuals with minimal additional training. However, despite its advantages, neonatology has limitations when applying POCUS. Interpretation is operator-dependent in experience and expertise, and mastery has a steep learning curve. It is not an overall pulmonary functional evaluation and should always be employed in concert with clinical evaluation and additional diagnostic methods.

**Conclusion**

Neonatal respiratory distress syndrome exists as a worldwide concern affecting all preterm babies. Early diagnosis, together with effective management, becomes essential since it affects neonatal mortality rates while impacting long-term outcomes. Respiratory disease outcomes show potential for improvement with point-of-care ultrasound technology and telemedicine through specialized care access, diagnosis capabilities, and correct treatment approaches. Through telemedicine technology, parents can access remote medical appointments to receive prompt care while preventing unsafe patient transports. At the same time, point-of-care ultrasound increases the ability to evaluate pulmonary pathologies within the bed where appropriate interventions can be made promptly. The potential drawbacks of these tools do not outweigh the advantages in optimizing neonatal patient outcomes. Medical progress constitutes a crucial element for decreasing the healthcare inequalities experienced by neonates, particularly in neonatology. Healthcare providers should, therefore, adopt these advances to reduce neonatal death rates and deliver better future outcomes for patients who have RDS.

**References**

Chuo, J., Makkar, A., Machut, K., Zenge, J., Jawahar Jagarapu, Abeer Azzuqa, & Savani, R. C. (2022). Telemedicine across the continuum of neonatal-perinatal care.
_Seminars in Fetal and Neonatal Medicine_,
_27_(5), 101398–101398. https://doi.org/10.1016/j.siny.2022.101398

Gjesteby, L. A., Pare, J. R., & Brattain, L. J. (2022). Ultrasound for the Emergency Department and Prehospital Care.
_Engineering and Medicine in Extreme Environments_, 209–234. https://doi.org/10.1007/978-3-030-96921-9_11

Padovani, P., Singh, Y., Pass, R. H., Vasile, C. M., Nield, L. E., & Baruteau, A.-E. (2023). E-Health: A Game Changer in Fetal and Neonatal Cardiology?
_Journal of Clinical Medicine_,
_12_(21), 6865. https://doi.org/10.3390/jcm12216865

Ying, Q., You, X., Luo, F., & Wang, J. (2021). Maternal-Neonatal Serum Albumin Level and Neonatal Respiratory Distress Syndrome in Late-Preterm Infants.
_Frontiers in Pediatrics_,
_9_. https://doi.org/10.3389/fped.2021.666934

November 5, 2026
[Solved] week 4.5

✓ Verified Academic Solution Available

Executive Solution Overview

discussion response – 2 years ago

Instant Solution Download
$6.99

Immediate access to the full model answer, formatted citations, and rubric breakdown.

Need a Fresh Custom Paper?

Have this question answered from scratch according to your specific instructions and deadline.
Order on TutorsGallery →

Assignment Prompt & Instructions

discussion response

– 2 years ago

November 5, 2026
[Solved] Lorem, Ipsum

✓ Verified Academic Solution Available

Executive Solution Overview

[>Astronomy homework help](https://www.sweetstudy.com/fields/physics-astronomy) Supported file types: jpg, png, pdf, doc, xls – 2 years ago

Instant Solution Download
$6.99

Immediate access to the full model answer, formatted citations, and rubric breakdown.

Need a Fresh Custom Paper?

Have this question answered from scratch according to your specific instructions and deadline.
Order on TutorsGallery →

Assignment Prompt & Instructions

[>Astronomy homework help](https://www.sweetstudy.com/fields/physics-astronomy)

Supported file types: jpg, png, pdf, doc, xls

– 2 years ago

November 5, 2026